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 ABSTRACT 
THE ROLE OF NOTCH3 IN T HELPER CELL DIFFERENTIATION AND 
INDUCTION OF MOUSE MODEL OF MULTIPLE SCLEROSIS EAE 
FEBRUARY 2016 
FURKAN AYAZ, BS., BOGAZICI UNIVERSITY 
PhD., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Prof. Barbara A. Osborne  
Th1 and Th17 are subsets of CD4
+
 T cells or T helper cells (Th). Th cells are the 
major adaptive immune cells involved in inflammation during the development of 
Multiple Sclerosis (MS). MS is a neurodegenerative autoimmune disease and one mouse 
model of the disease is Experimental Autoimmune Encephalomyelitis (EAE). 
Development and differentiation of Th1 and Th17 cells are regulated by the Notch family 
of trans-membrane proteins (Notch1, 2, 3 and 4). We and others have shown that 
pharmacological inhibition of Notch activity impairs Th1 and Th17 differentiation as 
well as development of EAE. However, it is not known which Notch family member or 
members play a major role in this process. In this thesis, by using Notch3 knockout mice, 
we demonstrate that Notch3 is one of the major regulatory members of Notch signaling 
that is involved in regulation of Th1, Th2, iTreg and Th17 polarization as well as pro-
inflammatory cytokine GMCSF production by Th cells. Impaired Notch3 signaling did 
not affect Th cell activation and proliferation. Our results demonstrate a previously 
unknown role of Notch3 in the development of pro-inflammatory Th cell types. We also 
report that non-canonical Notch signaling through PKCθ may play an important role in 
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Th17 differentiation. Development of EAE was not affected by impaired Notch3 
signaling which suggests a compensation mechanism by other Notch protein(s) that 
regulate the development of EAE in vivo.         
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CHAPTER 1 
INTRODUCTION 
1.1. CD4
+
 T cells (Th cell) Development and Function and their role in autoimmune 
diseases, such as Multiple Sclerosis  
T helper (Th) cell precursors (naïve CD4
+
 T cells) develop in thymus and migrate 
into lymph nodes after maturation. They are involved in tumor immunity, adaptive 
immunity to various pathogens, allergic responses, asthma and autoimmunity [1, 2]. Th 
cells help B cells to produce antibody, CD8
+
 T cells to enhance and maintain their 
function. They stimulate macrophage activity and define the type of response to a certain 
danger signal, such as a foreign antigen or self-antigen indicating wound in the tissue or 
dead cells or cancerous cells [1, 2]. After danger is removed or if the threat detected is a 
“self” molecule then in a healthy individual Th cells adopt a suppressive phenotype. This 
suppressive Th cells prevent immune responses damaging the tissue and eventually start 
wound healing processes [1, 2]. 
 These adaptive immune cells are activated specifically against an antigen 
presented via MHC class II molecules by antigen presenting cells (APCs) such as 
dendritic cells and macrophages [3, 4, 5, 6]. Antigen presentation to the T cell receptor 
(TCR) accompanied by a co-stimulatory signal from B7 molecules on APCs through the 
CD28 receptor, lead to activation of Th cells [5, 6]. Furthermore, the cytokine (small 
molecular weight secreted signaling molecules) environment helps to determine the fate 
of Th cells in terms of their function and activity [1, 2]. Activated Th cells have an 
increased rate of proliferation as well as increased expression of CD25 and CD69 surface 
markers [7, 8]. CD25 is a high affinity IL-2 receptor that is crucial in IL-2 signaling 
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which is one of the primary cytokines involved in immunity and tolerance by regulating 
immune cell activity [7, 8]. CD69 is a C-type lectin receptor that regulates T cell 
proliferation as well as signal transmission to intracellular environment. In our studies we 
measure CD25 and CD69 levels as indicator of Th cell activation in vitro [7, 8]. 
Depending on the cytokine profile in the macro-environment, Th cells differentiate into 
different sub-types: Th1, Th2, Th17, Treg and ThGMCSF [1, 2, 9]. These different cell 
types are mostly differentiated by the types of cytokines they produce as well as by the 
differential expression of cell surface molecules. Differential function in these Th cell 
sub-types is established by different gene expression profiles for each fate. Cytokine 
signaling further enhance or inhibit certain gene expression programs and eventually 
define the type of Th cell and response that would be most effective according to the type 
of danger detected [1, 2, 9]. 
In the following sections, I will give an overview of Th cell types, their 
development, function and role in autoimmunity especially in Multiple Sclerosis (MS).  
1.2. Th1 cell development and function  
In the presence of interleukin (IL)-12 and interferon (IFN)-γ cytokines, CD4+ T 
cells acquire an IFN-γ producing Th1 fate and these cells are effective against 
intracellular pathogens [1, 2, 10]. Th1 cells also produce IL-2, lymphotoxin α (LT-α), 
TNF-α and interleukin-10 (IL10) [1, 2]. Master regulators of gene expression program in 
Th1 cells are T-bet and STAT-4 [11, 12]. IFN-γ produced by Th1 cells increases the 
microbicidal activity of macrophages as well as increases the activation of CD8
+
 T cells 
[1, 2]. LT-α has been a disease progression marker in Multiple Sclerosis (MS) patients 
and LT-α deficient mice have less induction of the animal model of MS, Experimental 
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Autoimmune Encephalomyelitis (EAE). IL-2 produced by Th1 cells is imperative for 
memory formation especially in CD8
+
 T cells the role of IL-2 in memory cell formation 
has been shown more elaborately [1, 2, 13].  
Th1 cells are associated with autoimmune diseases due to increased inflammatory 
environment in the tissue [3, 4, 14]. In the case of MS, Th1 cells increase the activity of 
macrophages by IFN-γ that leads to increased production of radical oxygen species, 
phagocytic activity and production of inflammatory signaling molecules such as tumor 
necrosis factor (TNF)-α by macrophages [3, 4, 14, 15]. These activated macrophages lead 
to increased inflammation, axonal damage and eventually death of neurons in MS lesions 
[14, 15]. Furthermore, by regulating the activity of CD8
+
 T cells and the memory 
formation by them, Th1 cells regulate the progression of MS at another level [1, 2, 14, 
15]. CD8
+
 T cells are found in the inflammatory plaques formed in the central nervous 
system (CNS) of MS patients [14, 15, 16, 17, 18]. They can induce the death of neurons 
through their cytolytic molecules to further cause neurodegeneration [14, 15, 16, 17, 18]. 
Therefore, Th1 cells are one of the major pro-inflammatory players that modulate the 
inflammatory environment in the CNS of MS patients. 
1.3. Th2 cell development and function    
Interleukin (IL)-4 and IL-2 induce polarization towards IL-4, IL-5, IL-9, IL-10, 
IL-13, IL-25 and amphiregulin producing Th2 cells and these cells are effective against 
extracellular parasites such as helminths, and are associated with allergies and asthma [1, 
2, 19]. The master gene expression regulators in Th2 cells are GATA-3 and STAT-5 [1, 
2, 20]. IL-4 produced by Th2 cells have positive feedback effect on themselves as well as 
class switching in B cells to produce IgE antibodies [1, 2, 21]. Multivalent ligand and 
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immunoglobulin E (IgE) complex interacts with FcεRI receptors on mast cells and 
basophils leading the secretion of serotonin and histamine as well as production of 
cytokines such as IL-4, IL-13 and TNF-α [1, 2, 22, 23, 24, 25, 26]. Eosinophils are 
recruited to the tissue by IL-5 cytokines. IL-9 plays a role in activation of lymphocytes 
and mast cells as well as production of mucin by epithelial cells during an allergic 
reaction (27). IL-10 has suppressive function on Th1 differentiation and activity as well 
as dendritic cell activation [1, 2, 28]. IL-13 plays a role in the expulsion of helminths and 
induces airway hypersensitivity [22]. Amphiregulin is a signaling molecule in epidermal 
growth factor family, inducing the cell proliferation in epithelial cells. It has been shown 
that amphiregulin plays an important role in the expulsion of nematodes. There are 
studies suggesting a role for amphiregulin in airway hypersensitivity [1, 2, 29]. IL-25 (IL-
17E) signals through IL-17 receptor B (IL17RB) and induces IL-4, IL-5 and IL-13 
production by non-lymphocyte populations [30]. IL25 leads the further initiation and 
amplification of Th2 polarization. In response to allergens lung epithelial cells produce 
IL-25 to initiate a Th2 type of response. IL-25 is involved in the recruitment of 
eosinophils to the tissue by induction of CCL-5 (RANTES) and CCL-11 (eotaxin) 
production [1, 2, 30, 31]. 
In an MS setting, Th2 cells can be involved in B cell function by inducing 
antibody production and class switching but studies suggest that the induction of Th2 
responses may decrease the severity of MS due to decreased Th1 and Th17 polarization, 
which are the pro-inflammatory cell types primarily involved in the induction of MS [14, 
15].   
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1.4. Th17 cell development and function   
IL-6, IL-21, IL-23, and transforming growth factor β (TGF-β) or IL-1β induce the 
polarization of Th cells into Th17.  IL-17A, IL-17F, IL-21 and IL-22 producing Th17 
cells are effective against extracellular bacteria and fungi. They have been associated 
with autoimmune diseases [1, 2, 14, 15, 32, 33]. RORγT and STAT-3 are the master gene 
expression regulators for Th17 program [34, 35]. IL-17A and IL-17F are located in the 
same locus and hence are mostly regulated through similar mechanisms and are co-
expressed in most of the cases. They both signal through IL17RA chain of the receptor 
which further suggests the similarity in their signaling. IL-17A has higher affinity to 
IL17RA than IL-17F [1, 2, 36, 37]. IL-17A plays an important role in the inflammatory 
responses by inducing the production of IL-6 cytokine and CXCL-8 (IL-8) chemokine 
[36]. Neutrophils play an important role against bacteria and fungi, both IL-17A and IL-
17F recruit and activate neutrophils during infection [1, 2, 38]. Th17 cells produce IL-21 
as their positive feedback stimulator for further amplification as in the case of IFN-γ for 
Th1 cells and IL-4 for Th2 cells. IL-21 also plays role in dendritic cell, CD8
+
 T cell, B 
cell and natural killer cell activation [1, 2, 38, 39]. IL-6 or IL-23 leads to activation of 
STAT-3 pathway that enables production of IL-22 by Th17 cells [40]. The aryl 
hydrocarbon receptor (AHR) is a dioxin receptor and is expressed in Th17 cells in 
abundance to lead IL-22 production whereas TGF-β inhibits the expression of IL-22 by 
Th17 cells [41]. During acute liver inflammation IL-22 has a protective role [42]. IL-22 
leads to dermal inflammation and acanthosis induced by IL-23 [40] . There are studies 
supporting the role of IL-22 in mediating response against bacterial infections but the 
source of IL-22 in this case can be other innate cells other than Th17 cells [1, 2, 43]. 
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In an MS setting, Th17 cells positively contribute to inflammatory lesions in the 
CNS by recruiting more neutrophils to the region as well as by inducing activation of 
dendritic cells that can increase their pro-inflammatory and antigen presenting capacity. 
Along with Th1 cells, Th17 cells are one of the major contributors of neurodegenerative 
inflammation in the CNS during MS progression [14, 15].   
1.5. Treg cell development and function  
In the presence of TGF-β and IL-2 Th cells acquire an anti-inflammatory Treg 
fate and these CD25 and FoxP3 double positive cells produce IL-10, IL-35 and TGF-β 
suppressive cytokines [44, 45, 46]. Foxp3 and STAT-5 are the master regulators of gene 
expression program in Treg cells [1, 2, 47]. If the CD4
+
 T cells differentiate into Tregs in 
the lymph nodes depending on cytokine milieu then these cells are induced regulatory T 
cells (iTregs). There are also some Th cells that acquired Treg phenotype during 
development in thymus and these are known as natural Tregs (nTregs) [1, 2, 48]. The 
cytokines produced by activated Th cells modulate the immune response in a suppressive 
fashion and induce “self” tolerance. Increasing Treg cell numbers and efficiency is a 
potential treatment method for autoimmune diseases as well as prevention of allograft 
rejection. It has been shown that increasing Treg cell numbers and enhancing their 
function prevented the allograft rejection in mice [1, 2, 49]. One drawback of the 
approach is that increased Treg function would hamper tumor immunity as well as 
immune reactions against pathogens. IL-10, IL-35 and TGF-β produced by Tregs form 
the molecular basis of suppression. TGF-β is involved in positive feedback loop by 
producing more induced regulatory T cell (iTregs) from CD
+
 T cells in the periphery [1, 
2, 45]. In vivo studies suggest that TGF-β as a strong suppressive cytokine whereas in 
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vitro setting it does not seem to be required [45]. The role of IL-10 is well established in 
the suppression of inflammatory bowel disease. Treg specific deletion of IL-10 resulted 
in lung inflammation and spontaneous colitis [1, 2, 46]. It has been shown that IL-10 
plays an important role to decrease the severity of EAE at later stages of the disease [50]. 
Treg produced IL-10 maintains a homeostasis between the host and bacteria during 
Leishmenia infection, and eventually prevents a disruptive inflammatory response which 
is protective for the host [50]. IL-35 contributes to suppressive immunity by Tregs and it 
shares a common subunit with IL-12, IL-12 p35 [1, 2, 51]. 
In an MS setting, Tregs play an important role to induce tolerance to self-antigens 
and to suppress the inflammation. It could be useful to develop treatment methods that 
would induce Treg cell differentiation over pro-inflammatory Th17 and Th1 cell 
differentiations in MS patients to suppress neurodegenerative inflammation and 
eventually establish tolerance to self-myelin peptides that are presented as antigen to T 
cells [14, 15].    
1.6. ThGMCSF cell development and function 
There is a recent study showing the importance of GMCSF producing Th cells a 
newly defined Th cell subset that is required for the induction of EAE. GMCSF is a 
cytokine involved in the monocyte maturation into macrophages and their further 
activation to give a pro-inflammatory response [9, 52]. Sheng et al. showed that impaired 
STAT-5 signaling caused a decrease in the induction of EAE. IFN-γ and IL-17A 
production was similar between STAT-5 knockout and WT EAE induced mice CD4
+
 T 
cells whereas there was a significant decrease in GMCSF production by STAT-5 
knockouts compared to WT. They also demonstrated that IL-7 signaling induced GMCSF 
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production by CD4
+
 T cells by activation of STAT-5 pathway. The transcription factors 
and cytokine milieu required for Th cell differentiation into ThGMCSF are yet to be defined 
but this study implied an important role for ThGMCSF subset that can increase the activity 
of macrophages hence induce neurodegenerative inflammation in the CNS of MS 
patients. Therefore, further studies would be useful to better understand this Th cell type 
and their role in the induction of MS to find possible therapeutic approaches.  
1.7. Transcription factors that affect Th cell differentiation and fate determination 
In order to better understand Th cell activation and differentiation, it is important 
to know the intracellular mechanisms dictating their phenotype. Studies dissecting 
intracellular signaling molecules such as transcription factors can be fruitful in terms of 
defining more and specific targets to alleviate tissue degenerative inflammation during 
infection as well as autoimmunity.  
NFκB, NFAT and AP-1 are three transcription factors that are activated upon 
TCR signaling and by cytokine signaling. These transcription factors regulate the gene 
expression to determine cell fate into different Th subsets [2]. There is evidence 
supporting involvement of multiple transcription factors in the Th subset differentiation 
other than NFκB, NFAT and AP-1. Studies suggest multiple master regulators of gene 
expression for T helper cell subsets [2]. It is important to further understand the 
transcription regulation in Th cells since they can be potential targets to alleviate the 
severity of autoimmune diseases in clinical settings. We should also be careful about 
which transcription factor(s) or Th subsets that will be targeted since there is a fine 
balance between Th cell subsets in terms of fate determination. They mutually exclude 
each other’s differentiation programs, so one should be cautious about which Th subsets 
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to target in a certain disease setting not to worsen inflammatory response by pushing Th 
cell differentiation to a more robust inflammatory cell program.  
In the following sections, I will go into more details of signaling pathways and 
transcription factors that are involved in each Th cell subtype differentiation. 
1.8. Signaling pathways and transcription factors involved in Th1 cell development 
and function 
IFN-γ signaling leads to activation of STAT-1 pathway which later on induces the 
activation of T-bet, a Tbox family member as the master regulator of Th1 differentiation 
[53, 54]. T-bet knockout cells have deficiency in Th1 polarization and T-bet knockout 
mice develop severe asthma symptoms [55]. There is still IFN-γ production in T-bet 
knockout cells due to the Eoemes (Eomesodermin) transcription factor expression [56]. 
Eoemes is another T-box family member and is involved in IFN-γ production by CD8+ T 
cells [57]. During Th1 polarization there is upregulation of Eoemes which contributes to 
IFN-γ production. IL-21 partially decreases IFN-γ production by Th1 cells by decreasing 
Eoemes expression whereas T-bet expression remains intact [58]. This further supports 
the role of Eoemes in IFN-γ production during Th1 cell response and suggests that T-bet 
is still efficient enough in the absence of Eoemes for Th1 differentiation. 
IL-12 signaling leads to activity of STAT-4 [59]. STAT-4 further amplifies Th1 
polarization by directly inducing IFN-γ production to create a positive feedback loop for 
the Th1 program [60]. Independent of TCR activation, IL-12 and STAT-4 signaling axis 
together with and NFκB signal inducer can lead to IFN-γ production [61].  
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Runx3 is another transcription factor involved in IFN-γ production by Th1 cells 
[62]. It is involved in T cell development at early stages by inhibiting CD4
+
 T cell 
development and leading to generation of CD8
+
 T cells [63]. In Runx3 knockout cells 
IFN-γ production is substantially decreased compared to wild type ones under Th1 
polarizing conditions [62]. When Runx3 is overexpressed in Th2 cells, it leads to IFN-γ 
production independent of T-bet expression [64].  
Hlx is another transcription factor involved in Th1 polarization. Hlx transcription 
factor plays an important role in embryogenesis and hematopoiesis. T-bet leads to 
expression of Hlx, which then interacts with T-bet protein to enhance the expression of 
IFN-γ [65].   
1.9. Signaling pathways and transcription factors involved in Th2 cell development 
and function 
IL-4 signaling leads to activation of STAT-6 which is the major Th2 inducing 
factor [66, 67]. In vitro, STAT-6 deficiency leads to impaired Th2 polarization whereas 
in vivo Th2 responses and differentiation are intact independent of STAT-6 [67, 68].  
STAT-6 expression is sufficient and required for the expression of GATA-3, master 
regulator of Th2 polarization, under in vitro conditions [69]. 
When GATA-3 is overexpressed in Th1 cells, it leads to IL-4 production [70]. 
Impaired GATA-3 signaling totally abolishes Th2 polarization both under in vivo and in 
vitro conditions [71].  IL-5 and IL-13 promoters have GATA-3 binding sites whereas IL-
4 does not [72]. When GATA-3 was deleted in fully differentiated Th2 cells it leads to 
decreased IL-5 and IL-13 production whereas it does not affect IL-4 production [73]. 
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This observation is in line with the presence of GATA-3 binding sites on promoted 
regions of IL-5 and IL-13 but not on that of IL-4.  
IL-2 leads to STAT-5 activity and there are two types of STAT-5, STAT-5a and 
STAT-5b [74]. STAT-5 transcription factors are involved in cell proliferation and 
survival [75]. Strong STAT-5 signaling is required for Th2 polarization [76]. Despite the 
presence of STAT-5b, there is a substantial decrease in Th2 polarization when STAT-5a 
is impaired both in vivo and in vitro conditions [77]. STAT-5 directly binds to the DNase 
I hypersensitive sites (HSII and HSIII) in the second intron of IL-4 locus [78]. 
IL-4 production also is enhanced by c-Maf, which is upregulated under Th2 
polarizing conditions. c-Maf does not affect the production of other Th2 cytokines [79]. 
IRF-4 is another transcription factor required for Th2 polarization and its deficiency 
causes decreased IL-4 production [80]. GATA-3 overexpression rescues the decreased 
IL-4 production phenotype in IRF-4 deficient cells, suggesting that GATA-3 is 
upregulated by IRF-4 [81]. 
The IL-4 early inducible gene, Gfi-1, is also transiently activated by TCR 
signaling. Gfi-1 modulates upstream and downstream IL-2 signaling to select the growth 
of cells with high GATA-3 expression [82]. 
1.10. Signaling pathways and transcription factors involved in Th17 cell 
development and function 
RORγt is the master regulator of gene expression during Th17 polarization. It 
induces IL-17 production [83].  RORγt deficient mice have reduced EAE disease scores 
compared to wild type ones, due to decreased IL-17 production [84]. 
12 
 
RORα is a nuclear receptor related to RORγt and is upregulated during Th17 
polarization. It is not required for IL-17 production but when both RORγt and RORα 
were targeted, IL-17 production was completely abolished [85].  
IL-6, IL-21 and IL-23 signaling leads to activation of STAT-3 and is required for 
IL-17 production, since deletion of it abolishes IL-17 producing cells. In order to create a 
positive feedback loop, STAT-3 increases the expression of IL-23 receptor [86]. 
IRF-4 is another transcription factor playing a crucial role in Th17 polarization. 
IL-17 production is substantially decreased in IRF-4 knockout cells [87]. IRF-4 regulates 
RORγt expression without affecting FoxP3 expression and EAE cannot be induced in 
IRF-4 knockout mice [88]. 
1.11. Signaling pathways and transcription factors involved in Treg cell 
development and function 
 FoxP3 is the master transcriptional regulator for Treg cell fate [89]. TGF-β 
signaling leads to FoxP3 expression in Th cells [90]. Continuous FoxP3 expression is 
required for sustained Treg suppressive activity [89]. Overexpression of FoxP3 in Th 
cells creates anergic and suppressive phenotype [91]. IL-2 expression induces STAT-5 
activity and it may play a role in FoxP3 production by binding to its promoter region. 
There is a close relationship between Th2 and Treg polarization due to overlapping 
STAT-5 activity in both lineages [92]. When FoxP3 expression diminishes in later stages 
of Treg activity they acquire a Th2 cell like phenotype [93].    
My studies focus on development of T helper cells and their contribution to 
Multiple Sclerosis. In the context of MS, dendritic cells and macrophages present myelin 
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proteins and other molecules, and some others yet to be defined, as antigens to Th cells in 
the lymph nodes which then differentiate into Th1, Th2, Th17 and ThGMCSF cells [9, 14, 
15, 94].  Th1, Th2, Th17 and ThGMCSF cells migrate into the spinal cord and brain regions 
in response to chemokines secreted from the central nervous system (CNS) [9, 14, 15, 
94]. Once Th cells reach to CNS, they exacerbate inflammatory reaction by recruiting 
more innate immune cells to the neuronal areas and furthermore enabling activation of 
these innate immune cells [9, 94]. Th cells have certain plasticity in their differentiation 
program so in depending on the cytokine environment in the lymph nodes and later on at 
CNS their functional fates are determined [1, 2, 14, 15]. Under normal circumstances, 
eradication of danger by the inflammatory response is followed by immune suppression 
and wound healing. Induced regulatory Th cells (iTregs) and natural regulatory Th cells 
(nTregs) can suppress inflammation and, in MS, oppose the action of Th1, Th2, Th17 and 
ThGMCSF cells [1, 2, 9, 14, 15, 94]. 
In order to identify more specific targets for therapeutic approach in MS setting, 
signaling pathways determining the specific sub-type differentiation of Th cells have 
been widely studied. One of these pathways is the Notch signaling pathway that has been 
studied extensively by our lab and others. The study presented here focuses on the role of 
Notch3 in the Th cell differentiation and in the induction of EAE. Notch signaling 
pathway and its relevance to MS and EAE will be described in detail in another section. 
First, an overview of Multiple Sclerosis and EAE will be given in the following section.   
1.12. An overview of Multiple Sclerosis  
Multiple Sclerosis (MS) is a debilitating autoimmune disease associated with 
inflammation in the nervous system [14, 15]. It commonly begins in early adulthood and 
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nearly 2.5 million people are affected by it worldwide [95]. Northern European descents 
and women are more susceptible to the disease. Although genetic, life style, dietary and 
environmental risk factors, especially viral infections, have been implicated for the 
development of this autoimmune disease, the initiating event that leads to the 
development of the disease and immunological targets are not known [14, 15, 95]. The 
symptoms are highly heterogeneous between patients in the clinical setting. The most 
common form of the disease is the relapsing remitting MS (RRMS), where there is 
alternating periods of worsening in the disease symptoms and followed by the dissipation 
of the severity. Relapsing remitting MS is also followed by sustained deterioration during 
secondary progressive MS (SPMS). Due to numerous disease mechanisms MS is 
multifaceted syndrome. During remission the endogenous functional recovery 
mechanisms are activated in the nervous system [14, 15, 17, 18, 95, 96, 97]. 
There are studies supporting the role of genetic background on the induction of 
MS. There is 25% concordance level between identical twins to develop the disease, 
indicating the role of genetic factors on the induction of the disease at the same time 
suggesting involvement of other factors in the disease development [14, 15, 94, 95, 96, 
97]. Clinical and epidemiological studies support role for Epstein-Barr virus infection, 
smoking and lack of vitamin D in the serum as possible causatives of MS. As preventive 
strategies decreasing the cigarette usage and increasing sunlight exposure to boost 
vitamin D levels in the serum could be used at population level [14, 15, 94, 95, 96, 97].      
It is known that during disease progression the inflammation is sustained by 
reaction against myelin sheath proteins covering the neural cells in brain, optical nerve 
and spinal cord [14, 15, 95, 96, 97]. There have been studies stressing the importance of 
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T cells in the development of the disease [14, 15, 95, 96, 97]. T cells orchestrate the type 
of immune response manifested during a danger signal, which can be triggered by a 
foreign molecule as well as a truncated or mislocalized self-antigen [1, 2]. Follow up 
studies suggest that B cells have an important role in the disease induction especially 
since the most common diagnostic tool is detection of oligoclonal bands in the patients 
[14, 15, 94, 95, 96, 97]. Targeting B cells in MS setting seems to be the efficacious way 
according to recent studies. Detection of autoantibodies is further helpful in our 
understanding of the disease, one of which indicated potassium channel KIR4.1 as a 
target molecule in MS [94, 98]. 
Other than the role of inflammation and preventive therapies, studying the 
recovery phase of MS is fruitful to develop better therapy methods. During inflammation 
the oxidative damage and energy insufficiency lead to axonal damage [94, 99]. There are 
studies focusing more on functional recovery rather than cellular level recovery since 
overall result of therapy might be more efficient than focusing on just cellular level repair 
mechanisms that may not necessarily lead to a functional recovery [94, 100].  
The primary progressive form of MS is manifested in 10-20% of patients and 
most patients with the relapsing remitting form have transition to the progressive type. 
This transition is due to exhaustion of functional compensation mechanisms as well as 
mitochondrial damage that lead to expansion of existing lesions and trapping of 
inflammation behind the blood brain barrier [3, 4, 14, 15, 94, 101]. In relapsing remitting 
model of MS, there are treatments available to slow the progress and improve the 
symptoms but there is not any effective treatment against primary progressive type [3, 4, 
14, 15, 94, 101]. More studies are needed to delineate the mechanism of primary 
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progressive type and to find better treatment betters. One of the possibilities is that, for 
now, based on similarities in disease mechanisms, therapies used in Parkinson’s and 
stroke disease can be tried in MS setting, especially for the progressive type [101].  
During the early stages of the disease, lymphocytes migrate through blood-brain 
barrier (BBB) into the brain, spinal cord and optic nerves and lead to formation of the 
perivascular inflammatory lesions, plaques [14, 15, 18]. When these plaques are formed 
in the eloquent areas, it drives neurological deficits. The incidence of relapses and 
frequency of periodic breaches of BBB diminish with disease duration according to 
natural history studies [14, 15, 18]. So far there is no marker of peripheral blood 
mononuclear cells (PBMCs) associated with MS progression and activity and there is no 
immunological assay to predict the severity of the disease [14, 15, 18].  
Ongoing pathogenic neuroinflammation is evident by the presence of microglial 
activation in the white matter that appears macroscopically normal as well as lymphoid 
follicles in the leptomeninges of SPMS brains [102, 103]. Perivascular inflammatory 
lymphocytes with adjacent demyelination and axonal transection are histological 
hallmarks of acute MS lesions [16, 17]. CD4
+
 T cells, CD8
+
 T cells and myeloid cells 
form the majority of these perivascular inflammatory infiltrates. Genetic polymorphisms 
associated with the development of MS include CD4
+
 T cell associated molecules. 
Polymorphisms in major histocompatibility complex (MHC) class II molecules that 
govern CD4
+
 T cell activation are genetic risk factors associated with MS. Other 
examples of genetic polymorphisms associated with MS are interleukin-2 (IL-2) receptor 
α chain and interleukin-7 (IL-7) receptor α chain, these receptors are involved in T cell 
development, survival and activation [104]. 
17 
 
Studies in EAE, the animal model of MS, further support a critical role for CD4
+
 
T cells in autoimmune demyelination [14, 15, 105]. EAE and MS manifest similar 
clinical and histological symptoms or phenotypes. EAE can be induced in an array of 
mammalian species by vaccination against myelin peptide epitopes restricted to MHC 
class II molecules [105, 106]. Adoptive transfer of CD4
+
 T cells from EAE induced mice 
to unvaccinated mice can induce EAE and these studies are useful to dissect CD4
+
 T cell 
specific role of proteins associated with MS [14, 15, 105, 106]. T helper 1 (Th1) and T 
helper 17 (Th17) lineages are associated with encephalitogenic myelin specific CD4
+
 T 
cells and they produce interferon γ (IFN-γ) and interleukin-17 (IL-17) cytokines, 
respectively [14, 15]. Recent studies show a correlation in MS severity or development 
with increased IL17A, tumor necrosis factor α (TNF-α), IFN-γ positive and IL-17A+ IFN-
γ+ double positive PMBCs in RRMS patients [107, 108]. Chemokines involved in T cell 
as well as innate immune cells trafficking are higher in MS patients’ cerebrospinal fluid 
compared to those of patients with non-inflammatory neurodegenerative diseases. Direct 
evidence for autoimmune characteristics of the disease comes from clinical studies 
showing decrease in the disease progression or severity by immunomodulatory 
molecules, or drugs targeting T cell trafficking, growth as well as survival [109-117].  
The treatment of MS is limited to relieving the symptoms and suppressing the 
immune reactions non-specifically or blocking immune cell trafficking into the central 
nervous system through BBB, which compromise the host response to other infections 
and does not support the recovery of degenerated neurons [14, 15, 18, 94]. Therefore, it is 
important to further understand the disease mechanism at both immunological and neural 
recovery levels to develop better treatment options. In the following section, I will give 
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an overview of Notch signaling that is known to play an important role in T helper cell 
development as well as in the induction of EAE. 
1.13. An overview of Notch signaling 
Notch is a trans-membrane protein with four isoforms; Notch (1, 2, 3, 4) [Figure 
1]. It links the fate of neighboring cells through regulation of cell proliferation, apoptosis, 
survival and differentiation in multiple metazoan tissues [118-121]. There are structural 
and functional differences between the Notch family members. EGF repeats at their 
extracellular region varies between the members. This may enable differential affinity for 
the ligands. Notch1 and Notch2 family members have trans-activation domain (TAD) 
which enables their interaction with transcription regulators. Notch3 and Notch4 lack 
TAD domain [118-121]. All Notch family members have two nuclear localization signal 
domains except Notch4 which bares only one copy [118-121].  Notch family member 
specific transcriptional targets are yet to be determined. We cannot associate a specific 
member for the activation of a particular pathway or transcription of particular genes 
[118-121]. Mutations that perturb its function are associated with several different genetic 
disorders and cancers [118-121]. In canonical Notch signaling, interaction of Notch 
protein with cell bound ligand (Delta-like 1, 2, 3, 4 or Jagged 1, 2) on the cell surface 
results in cleavage of Notch, first by ADAM10 and ADAM17 proteases, followed by 
cleavage by the gamma secretase complex at the transmembrane region [118-121]. At the 
end of this process, the Notch intracellular domain (NICD) translocates to the nucleus 
and interacts with RBPJκ/CSL, a transcription repressor. Upon interaction with NICD, 
RBPJκ/CSL becomes a transcription activator for downstream target genes [118-121].  
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However, more recent studies reveal the existence of several other modes of 
Notch signaling generally referred to as non-canonical Notch signaling. Interestingly, 
many instances of non-canonical signaling are associated with potentially pathological 
conditions including cancer and activation of the immune system while many normal 
cellular processes require canonical Notch signaling. For example, it is likely that early 
development in the mammalian embryo requires canonical Notch signaling since deletion 
of RBP-Jk mimics deletion of Notch1. Several other physiological processes, such as 
maintenance of the intestinal epithelium, also require canonical Notch signaling. 
Therefore, it is possible that blockade of non-canonical Notch signaling may provide 
opportunities to inhibit some instances of pathological Notch signaling leaving many 
other normal physiological processes intact [122]. However, since non-canonical Notch 
signaling is not as well characterized as the canonical signaling pathway, more in-depth 
inquiries in this area are likely to reveal potential new targets to manipulate non-
canonical Notch signaling [122]. 
1.14. The role of canonical versus non-canonical Notch signaling in Th cells 
Notch signaling regulates some lineage decisions of hematopoietic cells, and 
enables generation of T cells at the expense of B and myeloid cells in the early stages of 
hematopoietic cell development. At later time points, Notch plays a key role in the 
survival, proliferation, and differentiation of T cells. Notch signaling also regulates the 
development of some innate lymphoid cells, marginal zone B cells from precursor B 
cells, megakaryocytes, and cytotoxic (CD8) T-cell lymphocytes (CTLs) [123-128].  
Notch is important in driving the differentiation of naïve CD4 T cells into specific 
T helper (Th) subsets and targeting Notch signaling in Th cells provides the opportunity 
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for immune modulation. Studies in our lab demonstrate that gamma secretase inhibitor 
(GSI) treatment, which prevents Notch activity by inhibiting the formation of 
intracellular cleaved Notch, significantly reduces Th1, Th17, and induced Treg (iTreg) 
polarization [129-131]. Studies by other labs using different methods to block Notch 
signaling showed that Th2 polarization is also driven by Notch signaling [132-136]. We 
demonstrated a significant decrease in Th1 and iTreg differentiation in conditional 
Notch1 knockout Th cells and through the use of conditional RBPJk knockout T cells, 
revealed that Notch regulates Th cell differentiation into different Th cell fates 
independent of RBPJk and hence is non-canonical [137]. Furthermore, our data showed 
that both activation and proliferation of CD4 T cells are not impaired by conditional 
deletion of RBPJk. Thus, CD4 T cell activation, proliferation, and differentiation all 
require non-canonical Notch signaling, and recent data from our lab suggest Notch, in 
conjunction with NF-kB, and regulate this non-canonical signaling in CD4 T cells [137]. 
The possibility that non-canonical Notch signaling may occur through activation of NF-
kB is not surprising since links between Notch and NF-kB have been documented by 
several groups including our own [137-141]. In cells of the immune system, Notch3 in 
collaboration with NF-kB is reported to cooperatively regulate FoxP3 expression [139]. 
Additionally, we recently reported that Notch1can initiate NF-kB activation via cytosolic 
interactions with components of the T cell signalosome [140, 141]. In particular, 
cytosolic Notch1 drives the formation of the CARMA1, BCL10, and MALT1 (CBM) 
complex that is essential for NF-kB activation in T cells. These data demonstrated that 
cytosolic, rather than nuclear, Notch1 drives CBM complex formation emphasizing the 
non-canonical role of Notch1 in this process [140, 141]. 
21 
 
In addition to Notch signaling through NF-kB, non-canonical Notch signaling is 
implicated in T cell metabolism and cell survival. Upon lymphocyte activation, there is 
an immense change in the metabolic activity of T cells to enable the production of 
building blocks for cell division and growth as well as ATP production [142-144]. This 
metabolic switch is closely linked with cell survival. As described above, Perumalsamy et 
al described a link between non-canonical Notch signaling and the mTORC2-Akt cascade 
[142]. In this report, they also provide evidence that cell survival of activated T cells is 
regulated by the interaction of cytoplasmic or membrane tethered NICD with the 
mTORC2-Akt cascade and this may also be involved in cell metabolism. The same group 
had previously demonstrated that interaction of Notch1and kinases involved in early T 
cell activation (PI3K and p56lck) regulates an anti-apoptotic program in T cells through 
Akt signaling [142]. Interestingly, another group has demonstrated mitochondrial 
localization of full length Notch1protein in neuronal cells providing additional evidence 
in another system for non-canonical Notch signaling in metabolism and cell survival 
[143]. 
Data also supports a role for PKCθ in non-canonical Notch signaling pathway. 
TCR activation in T cells leads to increased PKCθ activity which further activates 
downstream components: NFAT, AP-1 and NFκB to regulate gene expression [1, 2, 145]. 
Activation of these transcription factors enables cell survival and proliferation. PKCθ has 
been implicated in the downstream of Notch signaling pathway [1, 2, 145]. In my studies 
I performed some preliminary experiments by using pharmacological PKCθ and NFκB 
inhibitors to further examine the role of canonical versus non-canonical Notch signaling 
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in Th cell differentiation. In the following section, the role of Notch signaling in Th cell 
differentiation will be described based on recent studies. 
1.15. The role of Notch signaling in the development of Multiple Sclerosis and its 
mouse model EAE  
1.15.1. The role of Notch signaling in Th cell differentiation 
There are studies suggesting an important role for Notch signaling Th1 cells. 
When Delta1 ligands were used to activate Th cells, the cells were polarized towards Th1 
fate partly independent of IL-12 signaling [133, 134, 146-148]. Ectopic expression of 
Delta1 or Delta4 by bone marrow derived dendritic cells or APCs lead to increased Th1 
polarization [133,149, 150]. Overexpression of Notch3 intracellular domain but not the 
Notch1 intracellular domain in activated CD4
+
 T cells promoted T-bet expression and 
Th1 polarization. But further studies also suggested that overexpression of Notch1 causes 
increased T-bet expression and eventually increased Th1 polarization [129, 133, 146, 
151]. Furthermore, there are several studies showing that GSI treatment caused decreased 
IL-12 induced Th1 polarization in vitro. It has been shown that Notch directly regulates 
Tbx21 (T-bet) expression to promote Th1 polarization [129]. Studies have suggested a 
role for non-canonical Notch signaling through NFκB pathway on IFN-γ expression to 
drive Th1 polarization [137, 140, 141]. 
It was shown by the Amsen group that Delta1 expression by fibroblasts caused 
enhanced IFN-γ production by antigen stimulated Th cells [133]. The same group 
suggested that Notch1-Jagged1 signaling increased IL-4 production in Th cells, 
suggesting that Th2 polarization is enhanced through Notch1 and Jagged1 signaling 
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independent of IL-4/STAT-6 signaling [133]. They further expanded their studies by 
showing that Notch regulated Th2 polarization by inducing GATA-3 and enhancing IL-4 
production [133]. Other studies have shown that Th2 polarization was abrogated in the 
absence of both Notch1 and Notch2 signaling but not when either of them was impaired 
alone. Perturbed canonical Notch signaling also prevented Th2 function both in vivo and 
in vitro settings [134, 151].  
It has been shown that DLL4 expressing dendritic cells promote Th17 
polarization by inducing RORγt expression [135, 152, 153]. It has been shown that in an 
EAE setting Th1 and Th17 cells are prominent in the central nervous system and GSI 
treatment reduced Th1 and Th17 associated cytokines in EAE model as well as in in vitro 
settings [129, 154]. There are studies showing that DLL1 blocking antibody attenuated 
the induction of EAE whereas JAG1 blocking antibodies had an opposite effect, 
suggesting ligand dependent Th cell fate determination through Notch signaling [147].  
There is data suggesting that Jagged1 is involved in Treg polarization both in 
human and mouse cells [155]. Our recent paper has shown that Notch1 plays an 
important role in Th1 and Treg polarization independent of canonical Notch signaling 
[137]. Another study suggested that Jagged1 stimulation of Th cells in a mouse model 
resulted in increased Treg generation and decreased development of an experimental 
animal model of diabetes, an autoimmune disease [156]. According to literature none of 
the Notch signaling impairing mice had decreased natural Treg generation, suggesting a 
possible compensation mechanism between Notch family members or by other proteins 
[135]. Studies by Samon et al have shown that GSI treatment in Th cells decreased TGF-
β mediated FoxP3 expression, development and suppressive function of iTregs in vitro 
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[130]. Furthermore, GSI treatment of mice caused reduced FoxP3 expression and lead to 
development of autoimmune hepatitis. It was shown previously that autoimmune 
hepatitis resulted from decreased TGF-β signaling and Treg generation in mice [130, 
135]. It has been shown that Notch3 overexpression leads to increased FoxP3 levels in Th 
cells and increased Treg generation in mice that eventually impairs the induction of type 
1 diabetes in a mouse model [136, 157]. There are also studies suggesting a role for 
Notch signaling in the generation of Th9 subset but these require further examination 
[136, 158]. 
Overall, it has been shown by a multitude of studies that Notch signaling plays a 
significant role in Th cell differentiation and fate determination. In my studies, I further 
evaluated the role of Notch1 and Notch3 family members on Th cell differentiation as 
well as on the induction of EAE. In the following section I will summarize the role of 
Notch signaling in the induction of EAE and MS.  
1.15.2. The role of Notch signaling in the induction of EAE and MS 
There are studies suggesting the role of Notch signaling in MS and also its animal 
model EAE through two different angles. One way of Notch regulation of disease is by 
defining the cell proliferation, differentiation and survival of oligodendrocyte precursor 
cells which lead to generation of oligodendrocytes [159]. Oligodendrocytes are 
supportive cells of neurons and they are involved in generation of myelin proteins. 
Therefore, oligodendrocytes play a crucial role in the regeneration process of nervous 
system after MS lesions. It has been shown that Notch1 plays an essential role in 
oligodendrocyte precursor cell differentiation and maturation [159]. Depending on ligand 
type interacting with Notch1, the cell fate of oligodendrocyte precursor cells is 
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determined. If canonical Notch ligands are involved in the signaling process then target 
genes inhibit the maturation and differentiation of oligodendrocyte precursor cells. 
Whereas if non-canonical Notch ligands are the signal initiators then activated target 
genes lead to formation of oligodendrocytes from precursor cells to enable regeneration 
in the central nervous system [159].  
Canonical Notch signaling ligands are Delta, Serate/Jagged2 and Lag2 proteins. 
Example of non-canonical Notch signaling ligands in the central nervous system is 
F3/Contactin [159]. When chronic MS patient’s tissue samples were examined there was 
Jagged1 in abundance, which indicates the destructive face of Notch in the CNS [159]. 
Furthermore, aggregation of intracellular domain of Notch1 was detected in the 
oligodendrocyte precursor cells of patient samples. Instead of enabling the regenerative 
program, this aggregates seemed to start neurodegenerative program in these cells [159]. 
In summary canonical ligand induced Notch1 signaling in neurons has neurodegenerative 
role in MS setting which suggests that inhibition of non-canonical ligand induced Notch 
signaling might be a better treatment approach, but further studies are required to 
examine the role of other Notch family members in the process. 
The other way of Notch regulation for the induction of EAE and MS is through its 
role in Th cell proliferation, differentiation and activity [160]. It has been shown that Th 
cells play a major role in orchestrating an inflammatory response to the CNS proteins, 
especially against the antigens presented on oligodendrocytes, in MS and EAE [14, 15, 
160]. The role of Notch signaling in Th cell development and differentiation has been 
shown by a wide array of studies. In the light of those studies, GSI was used by Minter et 
al to observe its effect on the induction of EAE and there was decreased disease scores 
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compared to mock control treated groups [129]. Jurynczyk et al has shown that Notch3 
blocking antibodies were effective in impairing the induction of EAE compared to 
control treated group as well as Notch1 blocking antibody treated group, which gave 
similar results as control group [154]. One caveat of this study was that blocking 
antibodies and their effectiveness was not validated. Several independent studies have 
shown that blockage of DLL4, a notch ligand highly expressed on dendritic cells during 
MS and EAE, caused decreased EAE scores, immune cell infiltration to the CNS and, 
IFNγ and IL17A production compared to control mock treated group [161, 162]. Studies 
by Elyaman et al showed that DLL1 was another ligand that was highly expressed on 
dendritic cells during EAE and its blockage decreased inflammatory responses in CNS as 
well as induction of EAE compared to control mock treated group [163]. Studies have 
shown that inhibition of Jagged1 exacerbated EAE, therefore it is important to delineate 
the signaling mechanisms before targeting a certain group of proteins in EAE and MS 
settings [163]. The timing of drug administration is also crucial, since inhibition of 
Jagged2 before induction of EAE prevents the disease onset whereas concurrent 
inhibition of Jagged2 with the disease induction leads to increased disease scores [158].  
Overall, it is imperative to further study the role of Notch signaling, specific 
family members and ligands in T helper cell differentiation as well as induction of EAE, 
in order to design better therapy methods for MS patients. In the following section I will 
describe the rationale of our studies, specific aims and their significance for the field.   
1.16. Rationale, Specific Aim and Significance of the Project 
As summarized in the above sections, previous studies demonstrated that when 
Notch activation was inhibited by a pharmacological gamma secretase inhibitor (GSI) in 
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mice, there was a decrease in the development of Experimental Autoimmune 
Encephalomyelitis (EAE), a mouse model of MS, compared to untreated control mice. 
Under in vitro Th1 and Th17 polarizing conditions, GSI treated CD4
+
 T cells had 
impaired differentiation towards these fates compared to control CD4
+
 T cells. GSI 
prevents the gamma secretase complex mediated cleavage of all type I trans-membrane 
proteins, including all 4 Notch family members. Furthermore, GSI treatment has 
detrimental side effects on tissues requiring high Notch activity such as gut, therefore 
there is need to understand the specific details of which Notch protein(s) and downstream 
components of the pathway that affect Th cell differentiation [122]. 
In light of studies suggesting the role of Notch1 in Th cell development, we used 
conditional Notch1 knockout mice to study the role of Notch1 in Th cell differentiation as 
well as in the induction of EAE. Here, we are showing that Th17 differentiation as well 
as induction of EAE was intact when Notch1 signaling was impaired. These observations 
and recent studies showing the role of Notch3 by blocking antibodies in the induction of 
EAE as well as in Th1 differentiation by using siRNA for Notch3, lead us to the usage of 
Notch3 knockout animals for our further studies.   
Here, we used Notch3 Knockout (N3KO) mice from the Jackson Laboratory to 
study the effect of Notch3 on Th cell activation, proliferation and differentiation as well 
as on the induction of EAE [164]. As depicted in figure 2, these mice were generated by 
targeting exons 16 and 17 to prevent the generation of Notch3 protein. These mice don’t 
have any major phenotype. Notch3 N terminus is expressed in these mice CD4
+
 T cells 
whereas C terminus cannot be detected by q-RT-PCR. Under in vitro Th1, Th17 and 
iTreg polarizing conditions Notch3 was required for differentiation of CD4
+
 T cells to 
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these cell types. Moreover, impaired Notch3 signaling caused an increase in Th2 
polarization as well as GMCSF production under non-polarizing conditions. There was 
no difference in nTreg levels between wild type (WT) versus N3KO mice thymii.  
When EAE was induced in N3KO and WT control mice the disease scores and 
cytokines produced from these mice splenocytes were similar, suggesting a compensation 
mechanism under physiological conditions for Th cell polarization and the induction of 
EAE. Here for the first time, we demonstrate the role of Notch3 in Th1, Th17, Th2, iTreg 
polarization and GMCSF production by Th cells in vitro by using Notch3 knockout 
animals.  
Notch3 exerted its effect without influencing Th cell proliferation as well as 
activation in vitro. Our data suggest that inhibition of only one Notch family member in 
vivo was not sufficient to prevent the Th cell polarization towards pro-inflammatory type 
as well as the induction of EAE. Another significance of this study is that we suggest 
PKCθ as non-canonical target of Notch signaling to prevent Th17 polarization, major cell 
type involved in the induction of EAE. Combination therapy with GSI and PKCθ 
inhibitor, such as Rottlerin, might give promising results in prevention of EAE.   
In addition, we also used another N3KO mice strain generated differentially by 
the William Skarnes group to study Th cell differentiation [165]. These mice were 
generated by gene trap method where the disrupted gene and its product were 
characterized [165]. Only Notch3 gene and its protein product were disrupted in these 
mice [165]. As depicted in figure 3 there is not any major developmental phenotype in 
these mice but they develop CADASIL, a brain stroke disease [165]. In the CD4
+
 T cells 
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of these mice we can detect Notch3 N terminus whereas C terminus cannot be detected 
by q-RT-PCR. There was a tendency for increase in Th17 polarization based on IL17A 
production measured by ELISA. Since Th17 polarization results conflicted with previous 
studies showing importance of Notch signaling in Th17 polarization and the results of our 
siNotch3 knockdown and overexpression studies where impaired Notch3 signaling was 
decreasing Th17 polarization and overexpression of Notch3 caused significant increase in 
IL17A production, we did not further pursue the disease induction and other Th cell 
polarizations in this set of mice. 
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Figure 1: Notch family members 1, 2, 3 and 4 
There are structural and functional differences between the Notch family 
members. EGF repeats at their extracellular region varies between the members. 
This may enable differential affinity for the ligands. Notch1 and Notch2 family 
members have trans-activation domain (TAD) which enables their interaction with 
transcription regulators. Notch3 and Notch4 lack TAD domain. All Notch family 
members have two nuclear localization signal domains except Notch4 which bares 
only one copy 
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Figure 2: Generation of Jackson laboratory Notch3 knockout mice 
Exons 11 and 12 were specifically targeted to disrupt the production of Notch3 
protein. There is not any major developmental problem other than thinner arterial 
walls and ovary eptihelium. They do not develop CADASIL spontaneously. The 
N terminus of Notch3 is expressed in the CD4
+
 T cells whereas the C terminus 
cannot be detected by q-RT-PCR. 
 
 
 
32 
 
 
 
   
  
Figure 3: Generation of Skarnes Notch3 knockout mice 
Gene trap random method of recombination of exons 16 and 17 was used to 
disrupt the production of Notch3. Further characterization of the disrupted gene or 
genes was shown to be Notch3 only for these mice. There is not any major 
developmental problem and these mice develop CADASIL spontaneously. The N 
terminus of Notch3 is expressed in the cells whereas the C terminus cannot be 
detected by q-RT-PCR. 
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CHAPTER 2 
RESULTS 
2.1. Notch sparing GSI does not affect Th1 and Th17 polarization and, decreasing 
the expression of Notch1 does not prevent Th17 polarization as well as induction of 
EAE 
GSI targets all type I transmembrane proteins including Notch family members, in 
order to determine whether the effects we have observed with GSI on Th cell polarization 
were Notch signaling specific, we used a Notch sparing GSI, JLK6 [166]. JLK6 did not 
affect Th1 and Th17 polarization whereas GSI was able to inhibit differentiation of CD4
+
 
T cells into these fates (Figure 7). To further study the role of a specific Notch family 
member, Notch1, that has been shown to play an important role on CD4
+
 T cell 
development, we used conditional Notch1 knockout mice. In these mice Notch1 gene was 
floxed with Cre binding sites and Cre was under control of Mx promoter, which is 
activated by IFN signaling. PolyIC injection of mice as described in materials and 
methods section, lead to acute floxing (deletion) of Notch1 in CD4
+
 T cells. Under Th17 
polarizing conditions there was no difference in IL-17A production between control WT 
and conditional Notch1 knockout CD4
+
 T cells (Figure 7). When we induced EAE in the 
mice, the induction of the disease was similar between the groups (Figure 7). These 
suggested that Notch1 was not the primary signaling pathway in Th17 polarization as 
well as in the induction of EAE. Next, we focused on Notch3 whose role has been 
implicated in the induction of EAE by blocking antibodies as well as in Th1 polarization 
to further study Th polarization as well as the induction of EAE. 
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Figure 4: Notch sparing GSI does not prevent Th1 and Th17 polarization and, 
impaired Notch1 signaling does not affect Th17 polarization and the induction 
of EAE 
IFNγ and IL17A ELISAs for the supernatants of CD4+ T cells incubated in anti-
CD3 and anti-CD28 coated wells to activate T cell receptor under Non-Polarizing 
(NP), Th1 polarizing (Th1) and Th17 polarizing (Th17)conditions. A, IFNγ  ELISA 
for WT cells incubated for 72 hours in the presence of GSI and Notch sparing GSI 
(JLK6). B, IL17A ELISA for WT cells incubated for 72 hours in the presence of 
GSI and Notch sparing GSI (JLK6). C, IL17A ELISA for control WT (control) 
versus conditional Notch1 Knockout (cN1KO) cells were incubated for 72 hours 
under Th17 polarizing conditions. D, EAE scores of Control versus conditional 
N1KO knockout (cN1KO) mice at day 15. All data represent at least three 
independent experiments. Data represent the mean ± SEM, *p < 0.05, **p < 0.005, 
***p < 0.001. 
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2.2. Notch3 is expressed in CD4
+
 T cells after TCR activation and decreasing its 
expression impairs Th17 cell polarization 
In order to determine whether Notch3 was activated after T cell receptor (TCR) 
signaling, we did Q-RT-PCR for Notch3. According to our results Notch3 has the highest 
expression at 24 hour time point after TCR activation by plate bound anti-CD3 and anti-
CD28 and its expression decreases at later time points (Figure 5). In order to examine the 
role of Notch3 in Th17 polarization, shRNA plasmids targeting Notch3 expression or 
Notch3 intracellular domain (N3ICD) overexpression construct were delivered by viral 
infection .We did Q-RT-PCR to show the decreased or increased Notch3 expression in 
infected WT CD4
+
 T cells and our infection method was efficient enough to either 
decrease or increase Notch3 expression (Figure 6). When Notch3 was knocked down by 
lentiviral infection to deliver shRNA plasmid to the CD4
+ 
T cells, compared to control 
scrambled RNA plasmid infected cells there was a significant decrease in IL-17A 
production under Th17 polarizing conditions at 72 hour time point (Figure 6). We 
delivered (N3ICD) over-expression vectors through retroviral infection. Compared to 
cells infected with control scrambled RNA plasmid there was an increase in IL-17A 
production of N3ICD plasmid infected WT CD4
+
 T cells under Th17 polarizing 
conditions (Figure 6). These results suggested an important role for Notch3 in CD4
+
 T 
cells polarization of Th17 cells which play a major role in the induction of EAE and other 
autoimmune diseases. In order to further dissect the role of Notch3 in CD4
+
 T cell 
activity and differentiation we used Notch3 knockout mice (N3KO) in our experiments. 
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Figure 5: Notch1, Notch2 and Notch3 genes are expressed in CD4+ T cells 
throughout 96 hour time course 
A) Notch1 mRNA levels by q-RT-PCR in wild type (WT) CD4
+
 T cells at 24, 48, 
72 and 96 hour time points after incubation in anti-CD3 and anti-CD28 coated 
wells to activate T cell receptor. B) Notch2 mRNA levels for the samples in A C) 
Notch3 mRNA levels for the samples in A. All data represent at least three 
independent experiments. Data represent the mean ± SEM, *p < 0.05, **p < 0.005, 
***p < 0.001. 
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Figure 6: Knocking-down Notch3 expression causes decrease in IL17A 
production whereas over-expression of the intracellular domain of Notch3 
increases IL17A production by Th17 polarized wild type (WT) CD4+ T cells 
IL17A ELISA for the supernatants of CD4
+
 T cells incubated in anti-CD3 and anti-
CD28 coated wells to activate T cell receptor under Non-Polarizing (NP) and Th17 
polarizing (Th17) conditions. A) IL17A ELISA for scrambled control versus 
shNotch3 containing plasmid infected WT CD4
+
 T cells were incubated for 72 
hours. B) Notch3 q-RT-PCR for the samples from A. C) Cell viability for the 
samples from A and B. D) IL17A ELISA for scrambled control versus Notch3 
intracellular domain containing plasmid infected WT CD4
+
 T cells were incubated 
for 72 hours. E) Notch3 q-RT-PCR for the samples from C. F) Cell viability for the 
samples from D and E. All data represent at least three independent experiments. 
Data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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2.3. Impaired Notch3 signaling does not affect CD4
+
 T cell development, 
proliferation and activation 
For our experiments, we used Tom Gridley N3KO animals and in order to make 
sure that phenotypes that we would observe were independent of the early development 
defects in Th cell generation as well as defects in Th cell proliferation and activation, we 
measured CD4
+
 and CD8
+
 T cell levels in thymus and the spleen of WT versus N3KO 
mice and, rate of Th cell proliferation and activation marker levels in vitro comparing 
two mice groups. There was not any observable impairment in the development of CD4 T 
cells since the percentages of CD4
+
, CD8
+
 and CD4
+
CD8
+
 cells were similar in the 
spleen and thymus of WT and N3KO mice (Figure 7 and Figure 8). N3KO CD4
+
 T cells 
did not have any Notch3 expression, whereas WT cells were expressing Notch3 gene at 
72 hour time point (Figure 7). When we labeled the cells with CFSE to track the rate of 
cell proliferation there was no difference between WT and N3KO CD4
+
 T cells after 72 
hours of TCR activation (Figure 9). We measured the percentage and the expression 
levels of CD25 and CD69 surface markers as a way of examining the cell activation. 
There was no difference in the percentages and expression levels of CD25 and CD69 
between WT and N3KO CD4
+
 T cells after 72 hours of TCR activation (Figure 10). 
These results suggest that Notch3 did not affect CD4 and CD8 T cell development based 
on cell percentages and, the rate of cell proliferation and activation were not impaired 
when Notch3 signaling was abrogated. Next, we wanted to examine the role of Notch3 in 
T helper cell polarization by using these N3KO CD4
+
 T cells. 
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Figure 7: CD4+ T cells have reduced Notch3 expression in Notch3 homozygous 
knockout (N3KO) mice compared to wild type (WT) ones. CD4+ and CD8+ T 
cell numbers in the spleens of WT versus N3KO animals are similar 
A) Notch3 q-RT-PCR by using primers against C terminus of Notch3 in wild type 
WT versus Notch3 Homozygous Knockout (N3KO) CD4
+
 T cells incubated in anti-
CD3 and anti-CD28 coated wells to activate T cell receptor for 72 hours. B, C)  
CD4 staining and FACS analysis for wild type WT and Notch3 Homozygous 
Knockout (N3KO) splenocytes. D, E) CD8 staining and FACS analysis for wild 
type WT and Notch3 Homozygous Knockout (N3KO) splenocytes. F) CD4 to CD8 
ratio for the samples from B and D. All data represent at least three independent 
experiments. Data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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Figure 8:  CD4+ and CD8+ cell numbers in the thymii of WT versus N3KO 
animals are similar 
A) CD4 staining and FACS analysis for wild type WT and Notch3 Homozygous 
Knockout (N3KO) thymocytes, unstained control CD8-PE and CD4-PerCp 
antibodies. B) CD4 staining and FACS analysis for wild type WT and Notch3 
Homozygous Knockout (N3KO) thymocytes. C) CD8 staining and FACS analysis 
for wild type WT and Notch3 Homozygous Knockout (N3KO) thymocytes. D) 
CD4 to CD8 ratio for the samples from B and C.  
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Figure 9:  T cell receptor activation induced proliferation is similar between 
wild type (WT), Notch3 Heterozygous Knockout (N3Het), and Notch3 
Homozygous Knockout (N3KO) CD4+ T cells 
CFSE labeling and FACS analysis for wild type WT, Notch3 Heterozygous 
Knockout (N3Het), and Notch3 Homozygous Knockout (N3KO) CD4
+
 T cells 
incubated in anti-CD3 and anti-CD28 coated wells to activate T cell receptor for 72 
hours. 
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2.4. Notch3 signaling regulates CD4
+
 T cell polarization towards Th1, Th2, Th17 
and iTreg fates 
In order to study the role of Notch3 in Th1 cell polarization, we polarized CD4
+ 
T 
cells towards Th1 and measured the Th1 signature cytokine IFN-γ levels in the 
Figure 10:  T cell receptor activation induced CD25 and CD69 surface 
expression is similar between wild type (WT), Notch3 Heterozygous Knockout 
(N3Het), and Notch3 Homozygous Knockout (N3KO) CD4+ T cells 
A, B)  CD25 staining and FACS analysis for wild type WT, Notch3 Heterozygous 
Knockout (N3Het), and Notch3 Homozygous Knockout (N3KO) CD4
+
 T cells 
incubated in anti-CD3 and anti-CD28 coated wells to activate T cell receptor for 72 
hours. C, D)  CD69 staining and FACS analysis for wild type WT, Notch3 
Heterozygous Knockout (N3Het), and Notch3 Homozygous Knockout (N3KO) 
CD4
+
 T cells incubated in anti-CD3 and anti-CD28 coated wells to activate T cell 
receptor for 72 hours. 
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supernatants at 72 hour time point. Compared to WT cells Notch3 heterozygous knockout 
(N3Het) and N3KO cells had significant decrease in IFN-γ production under Th1 
polarizing conditions (Figure 11). To examine the role of Notch3 in Th17 differentiation, 
we measured IL-17A levels as the signature cytokine of Th17 cells. In N3Het and N3KO 
CD4
+
 T cells there was a significant decrease in IL-17A levels compared to WT cells 
under Th17 polarizing conditions (Figure 12). Literature supports imperative role of Th1 
and Th17 cells in the induction of EAE as they sustain inflammatory environment. To 
assess the role of Notch3 in iTreg polarization, we measured CD25
+
 FoxP3
+
 cell 
percentages. There was impaired iTreg polarization in N3KO CD4
+
 T cells compared to 
WT cells (Figure 14). When we measured nTreg levels in the thymus of N3KO mice 
compared to WT mice, the CD25
+
FoxP3
+
 cell percentages were similar (Figure 14). In 
order to examine the role of Notch3 in Th2 polarization, we measured IL-4 and IL-5 
levels as signature cytokine of Th2 polarization in the supernatants of Th2 polarized cells 
at 72 hour time point. There was increase in IL-4 and IL-5 levels between WT and N3KO 
CD4
+
 T cells (Figure 13). To study the role of Notch3 in GMCSF production, we 
measured GMCSF cytokine levels in the supernatants of non-polarized cells at 72 hour 
time point, there was an increase in GMCSF production by N3KO CD4
+
 T cells 
compared to WT ones (Figure 13).  Overall, there was a decrease in inflammatory Th1 
and Th17 cell polarization in vitro in N3KO mouse CD4
+
 T cells compared to WT ones. 
Whereas there was an increase in Th2 polarization and GMCSF production in N3KO 
cells compared to WT ones. Our next aim was examining the role of canonical versus 
non-canonical Notch signaling in Th17 polarization. 
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Figure 11: Notch3 regulates IFNγ protein levels in Th1 cells 
IFNγ and IL2 ELISAs for the supernatants of CD4+ T cells incubated in anti-CD3 
and anti-CD28 coated wells to activate T cell receptor under Non-Polarizing (NP) 
and Th1 polarizing (Th1) conditions. A, IFNγ ELISA for WT versus Notch3 
Heterozygous Knockout (N3Het) cells were incubated for 72 hours. B, IL2 ELISA 
for the samples in A. C, IFNγ ELISA for WT versus Notch3 Homozygous 
Knockout (N3KO) cells were incubated for 72 hours. D, IL2 ELISA for the samples 
in C. All data represent at least three independent experiments. Data represent the 
mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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Figure 12: Notch3 regulates IL17A production by Th17 cells 
IL17A and IL2 ELISAs  for the supernatants of CD4
+
 T cells incubated in anti-CD3 
and anti-CD28 coated wells to activate T cell receptor under Non-Polarizing (NP) 
and Th17 polarizing (Th17) conditions. A, IL17A ELISA for WT versus Notch3 
Heterozygous Knockout (N3Het) cells were incubated for 72 hours. B, IL2 ELISA 
for the samples in A. C, IL17A ELISA for WT versus Notch3 Homozygous 
Knockout (N3KO) cells were incubated for 72 hours. D, IL2 ELISA for the samples 
in C. All data represent at least three independent experiments. Data represent the 
mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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Figure 13: Notch3 regulates GMCSF, IL4 and IL5 production by CD4+ T cells 
GMCSF, IL4 and IL5 ELISAs for the supernatants of CD4
+
 T cells incubated in 
anti-CD3 and anti-CD28 coated wells to activate wild type (WT) versus Notch3 
Homozygous Knockout (N3KO)  T cell receptor under Non-Polarizing (NP) and 
Th2 polarizing (Th2) conditions. A, GMCSF levels after 72 hours. B, IL5 levels 
after 72 hours. C, IL4 levels after 72 hours. All data represent at least three 
independent experiments. Data represent the mean ± SEM, *p < 0.05, **p < 0.005, 
***p < 0.001. 
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Figure 14: Notch3 regulates iTreg polarization of CD4+ T cells, whereas it does 
not affect nTreg levels in Thymii of mice 
CD25-APC and FoxP3-PE double staining and FACS analysis for wild type (WT), 
Notch3 Heterozygous Knockout (N3Het), and Notch3 Homozygous Knockout 
(N3KO) CD4
+
 T cells incubated in anti-CD3 and anti-CD28 coated wells to activate 
T cell receptor for 96 hours. A) WT control representative data B) N3Het 
representative data, C) N3KO representative data. D) WT versus N3Het samples. E) 
WT versus N3KO samples. H) CD25 and FoxP3 double staining and FACS analysis 
for wild type (WT) and Notch3 Homozygous Knockout (N3KO) mice thymii. All 
data represent at least three independent experiments. Data represent the 
mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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2.5. Non-canonical Notch signaling PKCθ positively regulates Th17 polarization 
whereas NFκB has negative effect on Th17 differentiation and, RBPJκ dependent 
canonical Notch signaling is not required for Th17 polarization 
In order to examine the role of canonical versus non-canonical Notch signaling in 
Th17 cell polarization we used RBPJκ conditional knockout versus control WT mice as 
well as pharmacological inhibitors Rottlerin for PKCθ and Bay11 for NFκB signaling. 
When RBPJκ expression was decreased there was a tendency for increased IL-17A 
production in Th cell compared to WT ones under Th17 polarizing conditions (Figure 
15). This suggests a de-repressive effect of impaired RBPJκ signaling on Th17 
differentiation. In order to determine a non-canonical Notch signaling candidate required 
in Th17 polarization, we used NFκB inhibitor Bay11 since it has been shown that NFκB 
plays a role in Th1 polarization as well as in Notch signaling pathway. IL-17A 
production was significantly higher in Bay11 treated WT CD4
+
 T cells compared to 
DMSO treated control ones under Th17 polarizing conditions (Figure 15). In order to 
further assess the role of non-canonical Notch signaling in Th17 polarization we used 
PKCθ inhibitor Rottlerin. Studies have shown the role of PKCθ in Th cell activation as 
well as its interaction with Notch signaling pathway. IL-17A production was significantly 
decreased in Rottlerin treated WT CD4
+
 T cells compared to DMSO treated control ones 
under Th17 polarization conditions (Figure 15). Our results suggest that non-canonical 
Notch signaling through PKCθ positively regulates Th17 polarization whereas NFκB is a 
negative regulator of Th17 differentiation. Our next aim was examining the role of 
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Notch3 in the induction of an autoimmune disease model EAE by using WT versus 
N3KO mice. 
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2.6. Impaired Notch3 signaling does not affect the induction of EAE: 
Next, we were interested in whether the in vitro decrease in Th cell differentiation 
in Th1 and Th17 polarization would manifest itself in a physiologically relevant case, 
EAE. We used MOG35-55 peptide in complete Freund’s adjuvant (CFA) to induce EAE. 
Pertussis toxin was used to breach the blood brain barrier. When we induced EAE, 
compared to WT mice N3KO mice had similar disease scores throughout the 28 day time 
period (Figure 16). At the peak of the disease (15 days), we isolated the splenocytes of 
EAE induced mice and re-stimulated them in the presence of MOG35-55 peptide for 5 days 
Figure 15: Non-canonical PKCθ dependent Notch signaling regulates Th17 
polarization of CD4+ T cells 
IL17A  ELISA  for the supernatants of CD4
+
 T cells incubated in anti-CD3 and 
anti-CD28 coated wells to activate T cell receptor under Non-Polarizing (NP) and 
Th17 polarizing (Th17) conditions. A, IL17A ELISA for control WT (control) 
versus conditional RBPJκ Knockout (cRPJKO) cells were incubated for 72 hours. 
B, IL17A ELISA for WT cells incubated for 72 hours in the presence of gamma 
secretase inhibitor (GSI), PKCθ inhibitor (Rottlerin) and NFκB inhibitor (Bay11). 
Data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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(Figure 17). Compared to WT control, the re-stimulated splenocytes of EAE induced 
N3KO mice had significantly higher IFN-γ production whereas IL-17A and GMCSF 
production was similar (Figure 18). Similar IL-17A, GMCSF and increased IFN-γ 
production in the supernatants of EAE induced N3KO splenocytes are not in line with our 
in vitro observations for the role of Notch3 in Th1 and Th17 polarization. This 
discrepancy might be due to other cellular mechanisms in vivo to compensate impaired 
Notch3 signaling. 
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Figure 16: The induction of EAE is similar between wild type (WT) versus Notch3 
Homozygous Knockout (N3KO) mice (28 days) 
A) EAE disease scores of WT versus N3KO mice during 28 day time course (N=12 for 
each group).  
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Figure 17: The induction of EAE is similar between wild type (WT) versus 
Notch3 Homozygous Knockout (N3KO) mice 
A) EAE disease scores of WT versus N3KO mice during 15 daytime course. (N=12 
for each group)  
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2.7. Differentially generated William Skarnes Notch3 knockout mice gave a 
different phenotype for Th17 polarization: 
In order to further strengthen our observations we used a different N3KO mouse 
strain (Figure 19). There was no difference in CD4 and CD8 cell percentages as well as 
Figure 18: IFNγ production is higher by the MOG peptide restimulated 
splenocytes of EAE induced Notch3 Homozygous Knockout (N3KO) mice 
compared to wild type (WT) ones whereas IL17A and GMCSF levels are 
similar 
ELISAs for the supernatants of splenocytes incubated for 5 days with MOG peptide 
A) IFNγ ELISA. B) IL17A ELISA. C) GMCSF ELISA. N=8 for each group and 
data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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CD4 and CD8 double positive cell percentages in the splenocytes of WT versus N3KO 
mice (Figure 22). We polarized CD4
+ 
T cells towards Th17 and measured the IL-17A 
levels in the supernatants at 72 hour time point. Compared to WT cells, N3KO cells had 
higher tendency of IL-17A production under Th17 polarizing conditions (Figure 20). 
When we measured nTreg levels in the thymus of N3KO mice compared to WT mice, the 
CD25
+
FoxP3
+
 cell percentage was significantly higher in WT ones (Figure 21). When we 
labeled the cells with CFSE to track the rate of cell proliferation there was no difference 
between WT and N3KO CD4
+
 T cells after 72 hours of TCR activation (Figure 24). We 
measured the percentage and the expression levels of CD25 and CD69 surface markers as 
a way of examining the cell activation. There was no difference in the percentages and 
expression levels of CD25 and CD69 between WT and N3KO CD4
+
 T cells after 72 
hours of TCR activation (Figure 23). Since the Th17 polarization results were in conflict 
with previous studies showing the role of Notch signaling in Th17 polarization and also 
our siNotch3 experiment results, we did not further examine this mouse line. 
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Figure 19: Notch1, Notch2 and Notch3 gene expression levels in N3KO William 
Skarnes Mice 
A) Notch1 mRNA levels by q-RT-PCR in wild type (WT) vs N3 homozygous 
Knockout William Skarnes Mice (N3KO) CD4
+
 T cells at 72 hour time point after 
incubation in anti-CD3 and anti-CD28 coated wells to activate T cell receptor. B) 
Notch2 mRNA levels for the samples in A C) Notch3 mRNA levels for the samples in 
A. All data represent at least three independent experiments. Data represent the 
mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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Figure 20: Notch3 regulates IL17A production by Th17 cells 
IL17A ELISA  for the supernatants of CD4
+
 T cells incubated in anti-CD3 and anti-
CD28 coated wells to activate T cell receptor under Non-Polarizing (NP) and Th17 
polarizing (Th17) conditions. A, IL17A ELISA for WT versus Notch3 Homozygous 
Knockout (N3KO) William Skarnes cells were incubated for 72 hours. 
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Figure 21: Notch3 regulates nTreg levels in Thymii of mice 
CD25-APC and FoxP3-PE double staining and FACS analysis for wild type (WT) 
and Notch3 Homozygous Knockout (N3KO) William Skarnes mice thymii. A) 
Unstained control, B) WT double stained sample, C) N3KO double stained sample. 
D) Data represents at least three independent experiments for nTreg levels in WT vs 
N3KO. Data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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Figure 22:  CD4+ and CD8+ T cells in the splenocytes of WT versus N3KO 
animals are similar 
CD4-FITC and CD8-PE staining and FACS analysis for wild type WT and Notch3 
Homozygous Knockout (N3KO) William Skarnes splenocytes. A) CD4 staining 
and FACS analysis for wild type WT and Notch3 Homozygous Knockout (N3KO) 
William Skarnes splenocytes. B) CD8 staining and FACS analysis for wild type 
WT and Notch3 Homozygous Knockout (N3KO) William Skarnes splencoytes.  
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Figure 23: T cell receptor activation induced CD25 and CD69 surface expression 
is similar between wild type (WT) and Notch3 Homozygous Knockout (N3KO) 
CD4+ T cells 
A, B)  CD25-APC staining and FACS analysis for wild type WT and Notch3 
Homozygous Knockout William Skarnes (N3KO) CD4
+
 T cells incubated in anti-
CD3 and anti-CD28 coated wells to activate T cell receptor for 72 hours. C, D)  
CD69-FITC staining and FACS analysis for wild type WT and Notch3 Homozygous 
Knockout William Skarnes (N3KO) CD4
+
 T cells incubated in anti-CD3 and anti-
CD28 coated wells to activate T cell receptor for 72 hours. 
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Figure 24:  T cell receptor activation induced proliferation is similar between 
wild type (WT) and Notch3 Homozygous Knockout (N3KO) CD4+ T cells 
CFSE labeling and FACS analysis for wild type WT and Notch3 Homozygous 
Knockout William Skarnes (N3KO) CD4
+
 T cells incubated in anti-CD3 and anti-
CD28 coated wells to activate T cell receptor for 72 hours. 
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CHAPTER 3 
DISCUSSION 
It has been shown by our lab and others that Notch signaling plays an important 
role in the activation, proliferation and differentiation of Th cell sub-types [59, 60, 61, 62, 
63]. These studies were conducted by using pharmacological inhibition of gamma 
secretase which significantly decreases polarization of Th cells towards Th1, Th2, Treg 
and Th17 fates as well as the induction of EAE [59-63, 65, 66]. There are studies 
showing the role of Notch signaling in direct regulation of GATA-3 expression, hence 
Th2 polarization [59-63]. Recently our lab showed that Notch1 regulates activation, 
proliferation of Th cells and their differentiation towards Th1 and iTreg fates [64].  
In this study we have demonstrated that impaired Notch1 signaling did not affect 
the Th17 polarization of CD4
+
 T cells as well as the induction of EAE. There are 
limitations in this kind of studies with Notch1. Since the deletion of Notch1 is 
embryonically lethal and its specific deletion in CD4 T cells affect Th cell development 
we used a mouse model in which we could conditionally knockdown Notch1. Residual 
Notch1 might be enough to drive Th17 polarization and also the induction of EAE in our 
knockdown model. Since previous studies with GSI treatment as well as DLL1 and DLL4 
blocking antibody treatments already suggested that Notch signaling plays an important 
role in Th1 and Th17 polarization as well as the induction of EAE, we examined the role 
of another Notch family member in these processes [59-63, 65, 66, 68, 69]. 
There have been studies suggesting a role for Notch3 in T cell development, Th1 
polarization as well as development of EAE [59-63, 65-69]. By siRNA targeting Notch3 
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it was shown that Th1 polarization was impaired in vitro. Notch3 overexpression caused 
increased Th1 polarization in vitro [59-63]. In another study, EAE was induced by 
adoptive transfer of lymphocytes and during ex vivo incubation of these lymphocytes 
cells were incubated either control solvent or Notch3 blocking antibody [67]. According 
to their observations there was decreased EAE scores when Notch3 blocking antibody 
was used compared to control groups. One caveat of the study was that blocking ability 
and the specificity of Notch3 blocking antibody was not validated. Furthermore, how the 
disease induction was impaired was not demonstrated through mechanistic details. In this 
study we used a Notch3 knockout mouse generated by Tom Gridley group to further 
expand our understanding for the role of Notch3 in Th cell differentiation as well as in 
the induction of EAE [70]. These mice are viable with no observable negative phenotype. 
First time to our knowledge in this study, we have demonstrated that Notch3 is crucial in 
vitro since its impaired activity abrogated pro-inflammatory phenotype of Th cells by 
decreasing Th1 and Th17 polarization. Absence of Notch3 signaling altered the balance 
of Th cell polarization since there was increased Th2 polarization as well as GMCSF 
production by Th cells from N3KO animals compared to WT ones in vitro. Our in vivo 
data suggests that Notch3 is not sufficient for the induction of EAE since the disease 
scores in N3KO mice compared to WT ones were similar. This discrepancy in the in vitro 
versus in vivo results might be because of other compensatory mechanisms for Th1 and 
Th17 polarization in the splenocytes. Therefore, blocking Notch3 signaling only is not a 
promising candidate to impair pro-inflammatory Th cell differentiation in EAE setting as 
well as in MS.  
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Our data differs from previous studies showing that Notch3 blocking antibody 
decreased the EAE scores in an adoptive transfer model of EAE compared to control 
treated ones. Possible reasons for the different observations might be that in that study 
cells were treated ex-vivo for a certain period of time before adoptive transfer and that 
might lead to absence of compensatory mechanisms that would be effective in vivo in our 
setting where Notch3 is impaired from birth, hence resulted in decreased induction of 
EAE. In that study the role of Notch3 in Th cell differentiation was not delineated. In 
addition the Notch3 blocking antibody used in the study was not validated in terms of its 
blocking abilities and specificity (it might cross react with other Notch family members), 
which is a caveat of those studies. In this study we utilized CD4
+
 T cells from a N3KO 
mouse strain by Tom Gridley to further dissect the role of Notch3 on Th cell 
differentiation as well as on the induction of EAE. In order to support our observations 
we overexpressed or knocked down Notch3 gene expression by viral infection of CD4
+
 T 
cells and showed that Notch3 plays an important role in Th17 cell differentiation in vitro. 
There are studies demonstrating the role of Notch3 in Th1 cell polarization in vitro by 
knocking down or overexpressing Notch3 in mouse CD4
+
 T cells.  
Overall our results with this Notch3 knockout mouse strain from Gridley group 
show, that Notch3 positively regulates Th1 and Th17 polarization in vitro. We also 
unraveled a previously unknown role of Notch3 in negative regulation of both GMCSF 
production by Th cells and in Th2 polarization in vitro. Previously the role of Notch3 in 
nTreg development was shown by overexpression studies [72]. Our data supports the role 
of Notch3 in iTreg polarization of Th cells in vitro, whereas it does not affect nTreg 
development. This impaired iTreg polarization might be another reason why EAE scores 
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were similar between WT and N3KO mice. There was lack of immunosuppressive 
mechanisms and disease can be further induced by intact pro-inflammatory Th cell 
differentiation in N3KO mice. 
Our data demonstrates that CD4
+
 T cell activation based on the levels of CD25 
and CD69 markers, as well as cell proliferation are not affected by the impaired Notch3 
signaling. Therefore, Notch3 regulates Th1, Th2, Th17, iTreg development as well as 
GMCSF production by Th cells without affecting their rate of proliferation and level of 
activation. Based on our previous studies, GSI treatment and impaired Notch1 signaling 
perturbed Th cell activation and proliferation [57, 59-64]. We have also shown that 
impaired Notch3 signaling increased Th2 polarization and production of pro-
inflammatory cytokine GMCSF.  Intact Th cells activation and proliferation as well as 
increased Th2 polarization and GMCSF production might be other level of regulation that 
lead to our observations where the induction of EAE was similar between WT and N3KO 
Tom Gridley mice. 
Moreover, our data is novel to show that Th17 polarization is not regulated by 
RBPJκ dependent canonical Notch signaling. Data from our previous publications 
suggest that Th1 and iTreg polarization were through RBPJκ independent NFκB 
dependent non-canonical Notch signaling [64]. When we inhibited NFκB in Th17 cells 
there was a significant increase in IL-17A production compared to control non-treated 
cells. These suggest that NFκB is more important for Th1 and iTreg fates while doing so 
it may have inhibitory role on Th17 polarization program. Pharmacological inhibition of 
PKCθ suggests that Th17 polarization is positively regulated by non-canonical PKCθ 
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dependent Notch signaling. Further examination of these pathways at transcriptional and 
phosphorylation level is required. 
In order to further strengthen our observations about the role of Notch3 in Th cell 
differentiation and the induction of EAE, we also utilized from a mouse line generated by 
William Skarnes group to knockout Notch3 [71]. This mouse cells had Notch3 
extracellular protein trapped inside the cells. We could also detect Notch3 mRNA when 
N-terminus was targeted for amplification by primers in q-RT-PCR. CD4
+
 T cell 
activation as well as proliferation was similar between WT and this set of N3KO mice. 
nTreg cell percentage was significantly lower in N3KO mice thymii compared to WT 
ones. Th17 polarization of CD4
+
 T cells from these mice showed a tendency of higher 
potential compared to WT ones. This conflicted with our siNotch3 data as well as 
previous studies showing the role of Notch signaling in Th17 polarization. These mice 
also develop CADASIL syndrome spontaneously which would complicate our 
observations about the induction of EAE. Hence, we did not further study these mice. 
Discrepancy between Tom Gridley and William Skarnes Notch3 knockout mouse lines 
further suggests that differentially generated knockout mouse strains can give different 
results due to differences in the function of truncated protein either stimulating or 
blocking the signaling pathway. 
In conclusion, by using N3KO animals from Tom Gridley group we have 
revealed a previously unknown role of Notch3 in the regulation of Th1, Th2, Th17 and 
iTreg differentiation as well as GMCSF production by Th cells in vitro. This impaired 
pro-inflammatory Th cell differentiation in the absence of Notch3 was not reflected under 
physiological conditions. EAE scores of WT versus N3KO mice were similar. Possible 
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explanations might be compensatory signaling pathways that are missing in vitro 
conditions. Our data suggests that Th17 polarization is regulated by RBPJκ independent 
PKCθ dependent non-canonical Notch signaling. More studies should be done where 
combinatorial targeting of multiple Notch family members as well as other signaling 
molecules such as PKCθ is aimed to impair the induction of EAE. Pharmacological 
inhibition of NFκB significantly increased Th17 polarization in vitro, suggesting that we 
should be cautious about usage of NFκB inhibitors depending of disease context. Since 
there has been studies supporting the role of NFκB in Th1 polarization, inhibition of 
NFκB might be a better strategy for diseases lead by Th1 polarization but not by Th17 
polarization. 
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CHAPTER 4 
CONCLUSIONS AND FUTURE DIRECTIONS 
The role of Notch signaling in T helper cell differentiation and in the induction of 
EAE have been shown and studied but the field is still far from total understanding of the 
mechanism how  Notch signaling regulates Th cell differentiation as well as induction of 
EAE [1, 2, 4, 132-136]. Since Notch is involved in cell differentiation in many different 
types of cells and tissues, it is complicated to dissect its Th cell intrinsic or neuron cell 
intrinsic functions in EAE setting [3, 4, 167]. Another level of complexity comes from 
differential outcomes of different Notch ligand interactions to initiate the signaling event 
[167].  
In order to further dissect the role of Notch signaling in the induction of EAE and 
Th cell differentiation, we studied first the role of Notch1 signaling in the induction of 
EAE and Th17 polarization, major Th cell subtype involved in the induction of EAE. It 
has been shown by our lab previously that GSI prevents Th1 and Th17 polarization as 
well as the induction of EAE [129, 130]. Our recent publication clearly demonstrates that 
in conditional Notch1 knockout CD4
+
 T cells there was reduced Th1 polarization [159]. 
My data here shows that Th17 polarization as well as the induction of EAE was not 
affected in conditional Notch1 knockout mice. Possible reason might be residual Notch1 
activity in these mice after induction of gene knock down.  
Based on a study showing the preventive effect of Notch3 blocking antibody in 
mice that had EAE induction by adoptive transfer of lymphocytes, we have focused on 
the role of Notch3 in the induction of EAE as well as Th cell differentiation [154].  First 
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time in the literature, we are showing that Notch3 is indispensable for Th1, Th17 and 
iTreg polarizations in vitro, whereas it is inhibitory for Th2 polarization and GMCSF 
production by Th cells. Based on our in vivo data, Notch3 is not required for the 
induction of EAE and Th17 polarization as well as GMCSF production whereas its 
impaired activity lead to increased Th1 activity in vivo. A possible reason of this 
discrepancy is compensatory mechanisms that are effective in vivo system whereas are 
lacking in vitro. Another reason might be that Notch3 can be important for neural cell 
development. In future it would be informative to study the role of Notch3 in neurons and 
oligodendrocytes by isolating these cells from Notch3 knockout mice and further 
examining their characteristics to compare with those of wild type mice. Another future 
direction would be inducing EAE by adoptive transfer of lymphocytes into wild type 
mice from previously EAE induced Notch3 knockout and wild type mice to examine the 
disease scores and further focus on T helper cell intrinsic role of Notch3 in the induction 
of EAE. It would be useful to generate double knockouts of Notch1 and Notch3 to study 
the role of these two proteins in the induction of EAE, since our data suggest that Notch1 
and Notch3 are differentially important for Th cell differentiation in vitro.  
Based on our preliminary data NFκB is crucial for Th1 polarization whereas it 
inhibits Th17 polarization and PKCθ is crucial for Th17 polarization as well as Th1 based 
on other studies [1, 2, 159, 167]. Combination therapy targeting Notch signaling pathway 
and depending on disease type, Th1 or Th17 driven or  both Th1 and Th17 driven, 
inhibitors of NFκB and PKCθ can be used in future studies. Furthermore, interplay 
between Notch signaling and PKCθ as well as NFκB signaling pathways can be further 
dissected. 
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Overall, our results show that Notch3 plays an important role in Th cell 
differentiation by its interplay with NFκB and PKCθ signaling pathways in vitro. Notch3 
was not required for the induction of EAE in vivo, suggesting involvement of other 
protein families as well as other Notch proteins in the disease induction. Further studies 
delineating the role of Notch signaling and its partner signaling pathways in T helper cell 
differentiation and induction of EAE would be beneficial for finding new therapeutics in 
clinical settings. 
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CHAPTER 5 
MATERIALS AND METHODS 
5.1. Mice  
C57Bl6 and Notch3 Knockout mice were purchased from Jackson Laboratory and 
bred in our mouse facilities. . cNotch1KO and cRBPJκKO mice were generated by 
crossing Notch1
fl/fl
 or RBPJκfl/fl mice to mx1Cre+/- mice from Jackson Laboratory. Gene 
floxing was induced by 12-15 ug/g body weight injection of PolyI:PolyC (Amersham, 
Imgenex) every other day for 5 days. Injected mice are rested for 3 weeks then they are 
used for experiments. Age of mice to be used for experiments ranged between 7-13 
weeks old. All mice were housed at animal facilities according to guidelines of 
Institutional Animal Care and Use Committee at University of Massachusetts-Amherst. 
In order to, control the influence of microbiota on the induction of EAE cage beddings 
with excretions were exchanged between knockout and wild type control mice cages at 
least for one week while housing in the same animal facility. 
5.2. In vitro CD4
+
 T cell Culture and Polarizations  
Anti-CD4 magnetic beads (BD Pharmingen) are used to isolate CD4
+ 
T cells from 
splenocytes. 3x10
6
 cells/ml are plated on each well of 12 well plate coated with 1ug/ml of 
anti-CD3 (BD Pharmingen) and 1ug/ml of anti-CD28 (BD Pharmingen). RDG is used as 
media which consists of half and half mixture of RPMI and DMEM (LONZA) with 10% 
Fetal Bovine Serum (GIBCO), 5% L-Glutamine, 5% Na-Pyruvate, 5% 
Penicillin/Streptomycin (LONZA) and 0.1% β-mercaptoethanol. Th1 polarization is done 
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by adding 10ug/ml of anti-IL4 and 1ng/ml recombinant mouse IL12 (BD Pharmingen) 
into the culture media. Th2 polarization is done by adding 10ug/ml of anti-IFNγ and 
1ng/ml recombinant mouse IL4 (BD Pharmingen) into the culture media. Th17 
polarization is done by adding 10ug/ml of anti-IL4, 10ug/ml of anti-IFNγ (BD 
Pharmingen), 20ng/ml IL6 and 5ng/ml TGFβ1 (R&D systems) into the culture media (In 
some conditions 5ng/ml IL23 was also added into culture media (R&D systems)). For 
iTreg polarization CD4
+
CD25
-
 cells from bulk splenocytes are enriched by CD4 T cell 
enrichment set with 2.5ug biotin conjugated anti-CD25 (BD Pharmingen). Cells are 
activated in the presence of 2ng/ml of TGFβ1 (R&D systems). Cytokine levels in the 
supernatants are determined by standard ELISA assay (BD Pharmingen) after 72h 
incubation of cells. nTreg levels are measured in the thymus of mice by isolating the 
thymocytes and then doing CD25 surface and FoxP3 intracellular staining. CD4, CD8, 
CD25, and CD69 surface staining as well as FoxP3 intracellular staining are done at 72 
hour time point of cell activation and cells are analyzed on a FACS LSRII (Becton 
Dickinson). All antibodies are purchased from ebiosciences and intracellular staining for 
FoxP3 is done by following the instructions on ebiosciences FoxP3 intracellular staining 
kit.          
5.3. In vitro CD4
+
 T cell infection by lentivirus or retrovirus  
Anti-CD4 magnetic beads (BD Pharmingen) are used to isolate CD4
+ 
T cells from 
splenocytes. 1x10
6
 cells/ml are plated on each well of 12 well plate coated with 1ug/ml of 
anti-CD3 (BD Pharmingen) and 1ug/ml of anti-CD28 (BD Pharmingen). Before 
polarization of cells, they are infected either with control (pLKO.1) or shNotch3 lentiviral 
(Dharmacon) supernatants or Notch3 intracellular over-expression construct (Addgene) 
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containing retroviral supernatants. Viral supernatants are generated by transfecting 293T 
cells with 4ug viral construct plasmid and 4ug of coating vectors. Media of transfected 
293T cells is used after 72 hours by filtering with 0.45uM filters. Spin infection of cells is 
done at 30
°
C for 90 mins at 2500rpm in 500ul volume of viral or control supernatants in 
the presence of Polybrene. Then extra RDG is added into each well and plates are put in 
37
°
C incubators for 72 hours. RDG is used as media which consists of half and half 
mixture of RPMI and DMEM (LONZA) with 10% Fetal Bovine Serum (GIBCO), 5% L-
Glutamine, 5% Na-Pyruvate, 5% Penicillin/Streptomycin (LONZA) and 0.1% β-
mercaptoethanol. Th17 polarization is done by adding 10ug/ml of anti-IL4, 10ug/ml of 
anti-IFNγ (BD Pharmingen), 20ng/ml IL6 and 5ng/ml TGFβ1 (R&D systems) into the 
culture media Cytokine levels in the supernatants are determined by standard ELISA 
assay (BD Pharmingen) after 72h incubation of cells. 
5.4. Isolation of RNA and Q-RT-PCR analysis for Notch3 
Activated CD4
+
 T cells are washed in PBS and then cell pellet is lysed to isolate 
mRNA by using Ambion (Life Technologies) RNA extraction kit protocol and reagents. 
Reverse transcription is done by using PROMEGA reverse transcription reagents and 
following the manufacturer directions. TAKARA SYBR green is used to do quantitative 
PCR by targeting C-terminus of Notch3 (Exon 32 and exon 33) and for Q-PCR the 
manufacturer directions are followed.  
5.5. Inhibitor Treatments of CD4
+
 T cells 
3x10
6
 cells/ml are treated with 0.1% DMSO, 25uM ILCHO (Gamma secretase 
inhibitor (GSI)), 5uM JLK6 (Notch Sparing GSI), 1uM Bay11 (NFκB Inhibitor) and 3uM 
74 
 
Rottlerin (PKCθ inhibitor) for 30 minutes in 37°C water bath then they are plated into 
anti-CD3 and anti-CD28 coated 12 well plates. In vitro polarizations are done as 
explained in section 2.2.  
5.6. CFSE Proliferation Assay 
Cells are counted and 2x10
6
 cells/ml are re-suspended in PBS 0.1% BSA. 5mM of 
CFSE is added to the cells after mixing well cells are incubated in 37
°
C water bath for 10 
minutes. Then, 5x volume of ice-cold media is added onto cells and incubation is done on 
ice for 5 minutes. After centrifugation cells are washed in cold media then plate for 
activation or polarization. At the end of time 72 hour time point Flow Cytometry analysis 
is done for CFSE.  
 5.7. Induction of EAE and re-stimulation of EAE induced mice splenocytes 
 Hooke’s Kit (EK-2110) and protocol are used on female mice with C57Bl6 
background after 10 weeks of age. Disease progression is scored according to following 
scale: 0- No disease, 1- Limp Tail, 2- Hind Limb Weakness, 3- Hind Limb Paralysis, 4- 
Hind and Fore Limb Paralysis and 5- Morbidity and Death. Mice are anesthetized and 
splenocytes were isolated from the spleens of EAE induced mice and are re-stimulated in 
non-coated 24 well plates in RDG media for 5 days with 5x10
6
 cells/ml concentration, in 
the presence of MOG 35-55 antigen (Hooke’s Kit DS-0111) with 0, 10 and 20ug/ml 
concentrations. Supernatants of cultures are collected for ELISA analysis of IFNγ, 
GMCSF and IL17A cytokines.  
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5.8. Statistical Analysis  
GraphPad Prism Software version 5 is used to perform statistical analysis by 
unpaired two tailed student’s t-test for cell polarizations and Q-RT-PCR results, and two-
way ANOVA for EAE scores. 
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Table 5.1: List of Reagent Used as ELISA kits, Blocking antibodies and growth 
factors (continued onto next page) 
 
Reagent Name Vendor Catalog Number 
Mouse IL17F DuoSet 
ELISA 
R and D Systems DY2057 
Recombinant Human 
TGF-β1 
R and D Systems 240-B-002 
Anti-mouse GMCSF 
Purified 
eBioscience 14-7331 
Anti-mouse GMCSF 
Biotin 
eBioscience 13-7332 
Mouse GMCSF 
Recombinant Protein 
eBioscience 14-8331 
Purified Rat anti 
mouse IFNγ 
BD Pharmingen 554409 
Recombinant Mouse 
IL6 
R and D Systems 406-ML-005/CF 
Recombinant Mouse R and D Systems 403-ML-010 
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IL3 
Recombinant Mouse 
SCF/c-kit Ligand 
R and D Systems 455-MC010 
PolyIC HMW 
VacciGrade 
InvivoGen Vac-pic 
Recombinant Mouse 
IL23 
R and D Systems 1887-ML-010 
Recombinant Mouse 
IL4 
R and D Systems 404-ML-010 
Recombinant Mouse 
IL2 
BD Pharmingen 550069 
Anti-Mouse/Rat 
FoxP3-PE 
eBioscience 12-5773 
Avidin Horseradish 
Peroxidase (HRP) 
BD Pharmingen 554058 
Mouse CD4 T 
Lymphocyte 
Enrichment Set-DM 
BD Imag 558131 
Purified Rat Anti- BD Pharmingen 554424 
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mouse IL2 
Purified Rat Anti-
mouse IL17A 
BD Pharmingen 555068 
Biotin Rat Anti-
mouse IL17A 
BD Pharmingen 555067 
Purified NA/LE Rat 
Anti-Mouse IL4 
BD Pharmingen 554432 
Purified NA/LE Rat 
Anti-Mouse IFNγ 
BD Pharmingen 554408 
Recombinant Mouse 
IL17F 
R and D Systems 421-ML-025/CF 
Anti-Mouse CD4 
Magnetic Particles 
DM 
BD Imag 551539 
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Table 5.2: List of Primers Used for Genotyping of Mice and Q-RT-PCR 
Experiments (continued onto next page) 
 
Primer Name Usage Sequence (5’ to 3’) 
N3 Mutant Reverse 
Tom Gridley 
Genotyping of Tom 
Gridley Mice 
GGTACTGAGAACCAAACTCAG 
N3 Mutant 
Forward Tom 
Gridley 
Genotyping of Tom 
Gridley Mice 
TCGCCTTCTATCGCCTTTCTTG 
N3 Wild Type 
Reverse Tom 
Gridley 
Genotyping of Tom 
Gridley Mice 
CACATTGGCACAAGAATGAGCC 
N3 Wild Type 
Forward Tom 
Gridley 
Genotyping of Tom 
Gridley Mice 
CGATGAGGATGCTATCTGTGAC 
Notch3 Exon 16 
Forward William 
Skarnes  
Genotyping of 
William Skarnes 
Mice 
GATCAAGACATTGACGACTGTGAC 
Notch3 Exon 17 
Reverse William 
Genotyping of 
William Skarnes 
GTCGAGGCAAGAACAGGAAAAG 
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Skarnes  Mice 
Notch3 Trap 
Forward William 
Skarnes 
Genotyping of 
William Skarnes 
Mice 
GCAGGGAGAGTTGAGATGGAAGG 
Notch3 Trap 
Reverse William 
Skarnes 
Genotyping of 
William Skarnes 
Mice 
CCGTCACTCCAACGCAGCACCATCAC 
Notch3 Exon 32 
Forward 
Q-RT-PCR to detect 
C-Terminus of 
Notch3 
TGGGAAATCTGCCTTACACTGG 
Notch3 Exon 33 
Reverse 
Q-RT-PCR to detect 
C-Terminus of 
Notch3 
AGCAGCTTGGCAGCCTCATAG 
Actin Forward Q-RT-PCR to detect 
Actin 
GGCTGTATTCCCCTCCATCG 
Actin Reverse Q-RT-PCR to detect 
Actin 
CCAGTTGGTAACAATGCCATGT 
Notch1 Forward Q-RT-PCR to detect 
Notch1 
CCCTTGCTCTGCCTAACGC 
Notch1 Reverse Q-RT-PCR to detect GGAGTCCTGGCATCGTTGG 
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Notch1 
Notch2 Forward  Q-RT-PCR to detect 
Notch2 
ATGTGGACGAGTGTCTGTTGC 
Notch2 Reverse Q-RT-PCR to detect 
Notch2 
GGAAGCATAGGCACAGTCATC 
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APPENDIX 
IMMUNOMODULATORY ROLE OF NANOPARTICLES AND BACTERIAL 
MACROMOLECULES  
A.1. Immunomodulatory effects of nanoparticles in immune-challenged systems 
The ability of nanoparticle surface functionalities to regulate immune responses 
during an immunological challenge (i. e. inflammation) would open new doors for the 
therapeutics. We used functionalized 2nm core gold nanoparticles to control the innate 
immune responses of in vitro and in vivo systems activated with an inflammatory 
challenge. The results showed that hydrophobic zwitterionic functionalities dramatically 
boost inflammatory outcomes while hydrophilic zwitterionic structures generate minimal 
immunological responses. Surprisingly, tetra(ethylene glycol) headgroups generate a 
significant anti-inflammatory response both in vitro and in vivo. These results 
demonstrate the ability of simple surface ligands to provide immunomodulatory 
properties, making them promising leads for the therapeutic usage of nanomaterials in 
diseases involving inflammation. 
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A.2. Suppressive role of Exopoylsaccharide (EPS) in the induction of EAE 
Beneficial microbes modulate host immune responses, but in most cases, the 
mechanism by which bacterial molecules affect these responses is poorly understood.  It 
has been demonstrated that a single oral dose of Bacillus subtilis prevents disease 
induced by the enteric pathogen Citrobacter rodentium.  Protection was not due to 
reduced pathogen colonization or to changes in intestinal permeability.  Instead, it 
appears that protection was mediated by immune modulation.  Recently, 
exopolysaccharide (EPS) was identified as the protective molecule of B. subtilis [168].   
EPS binds F4/80
+
CD11b
+
 peritoneal macrophages, and in preliminary studies, 
treatment of mice with clodronate-loaded liposomes to deplete macrophages, prevented 
EPS-mediated protection from C. rodentium- induced disease, suggesting that 
macrophages are required for protection. Intraperitoneal injection of EPS increases the 
number of peritoneal anti-inflammatory M2 macrophages (M2MΦ), and the protective 
effects of EPS can be adoptively transferred to naïve wildtype (WT) mice using 
macrophage-rich peritoneal cells from EPS-treated WT mice, hypothesized to be a co-
receptor of TLR-4, and test if binding induces resident macrophages to become anti-
inflammatory M2MΦ [Unpublished data].  M2MΦ are potent anti-inflammatory cells 
known to inhibit T cell activation, and much of the pathology observed during C. 
rodentium infection results from excessive Th1 and Th17 responses.   
Our goal with the collaborators was to elucidate the role of EPS in prevention of 
experimental autoimmune encephalomyelitis (EAE) (Figure 25 and Figure 28). Our 
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preliminary data suggest that there is decrease in GMCSF production from MOG peptide 
restimulated splenocytes of EAE induced mice 3 days pre-treated with EPS compared to 
control animals (Figure 27). IL-17A production was similar between the groups but IFN-
γ production was higher in PBS mock control treated group compared to 3 days EPS pre-
treated group (Figure 27). These data suggest that EPS blocks GM-CSF production for 
pathogenic T cells and support the current hypothesis in the EAE field that GMCSF is the 
critical cytokine for the production of encephalitic T cells. According to our preliminary 
results, when EPS was injected the day of EAE induction the IL-17A and GMCSF 
production was similar between PBS injected control group and EPS injected groups 
(Figure 26). Whereas IFN-γ production was higher in the EPS treated group splenocytes 
compared to that of PBS treated group (Figure 26). Discrepancy between the results 
obtained between different experiments might be due to possible deviation encountered 
in the induction of EAE. Therefore, more experiments are required to done to reach 
statistically interpretable data.   
Additionally, it is known that TGF-β can block the development of GMCSF 
producing Th17 cells [1, 2].  Since M2 MΦ produce TGF-β, these data drive our 
hypothesis that EPS treatment is protective against EAE through the development of M2 
MΦ that produce TGF-β which, in turn, suppresses the formation of GMCSF producing 
encephalitic T cells.  In future studies, we will investigate the mechanism by which EPS 
protects from and ameliorates inflammatory disease, EAE and also begin studies to 
determine if EPS functions in humans. 
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Figure 25: The induction of EAE is lower in EPS injected animals compared to 
control ones 
A) EAE disease scores of WT  PBS injected control versus WT EPS injected group 
during 15 day time course. EPS injections started at day 0 of EAE induction. (N=8 
for each group)  
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Figure 26: IFNγ production is higher by the MOG peptide restimulated 
splenocytes of EAE induced EPS treated mice compared to control group 
whereas IL17A and GMCSF levels are similar 
ELISAs for the supernatants of splenocytes incubated for 5 days with MOG peptide 
A) IFNγ ELISA. B) IL17A ELISA. C) GMCSF ELISA. N=8 for each group and 
data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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Figure 27: The induction of EAE is abolished in EPS pre-treated (day -3) 
animals and lower in EPS injected (day 0) animals compared to control ones 
A) EAE disease scores of WT PBS injected control versus WT EPS injected group 
at day 0 of disease induction and WT EPS injected group at day -3 of disease 
induction (PRE EPS) during 15 day time course. (N=4 for each group)  
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Figure 28: GMCSF production is higher by the MOG peptide restimulated 
splenocytes of EAE induced PBS treated animals compared to EPS treated 
mice whereas IL17A and IFNγ levels are similar 
ELISAs for the supernatants of splenocytes incubated for 5 days with MOG peptide 
A) IFNγ ELISA. B) IL17A ELISA. C) GMCSF ELISA. N=4 for each group and 
data represent the mean ± SEM, *p < 0.05, **p < 0.005, ***p < 0.001. 
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A.3. Differential effect of Notch1 localization in the induction of T-ALL, 
implications of non-canonical Notch signaling 
Canonical Notch signaling is initiated by γ-secretase mediated cleavage of the 
Notch receptor, leading to the release of the active intra-cellular domain of Notch that 
migrates to the nucleus and interacts with RBP-Jκ, resulting in the activation of 
downstream target genes. While canonical Notch signaling is well known to play an 
active role in several steps during development as well in multiple cell fate decisions, 
recent evidence from both invertebrate as well as vertebrate systems indicate non-
canonical, RBP-Jκ independent signaling is important in several cellular processes [122].  
These observations raise the possibility that, through an understanding of non-canonical 
Notch signaling, novel strategies for inhibiting Notch signaling may prove useful in the 
design of therapies targeted to block aberrant Notch activity.  
The first indication for a role of Notch pathway in oncogenesis came from the 
studies of Aster and Pear in T-cell acute lymphoblastic lymphoma (T-ALL). 
Chromosomal translocation of the Notch1 gene was identified as a cause of T cell 
oncogenesis [169, 170]. Subsequently, the Notch pathway has been associated with 
tumorigenesis and cancer progression in the other cancers including: breast, ovarian, 
cervical, lung, prostate carcinomas, gliomas, and mesotheliomas [171-179]. Notch 
signaling regulates proliferation, differentiation and survival of tumor cells [180, 181] 
and is reported to be involved in maintaining the stem cell-like characteristics of cancer 
stem cells while giving rise to pluripotent neoplastic cells [182-184]. It is also required 
for further progression of differentiated cancer cells by regulating the metabolism, 
survival and transcription in these cells. In addition to its role in tumorigenesis, Notch 
90 
 
also has been reported to act as a tumor suppressor in certain cell types such as skin 
epithelium [185].  This observation makes it quite clear that an understanding of Notch 
signaling pathways are essential if therapeutic manipulation of Notch is likely to be 
successful.  
Inhibition of γ-secretase does not block all Notch related functions in tumor cells, 
suggesting a role for the non-canonical Notch signaling in transformed cells [171, 172, 
174-176, 179]. Additionally, transformation of baby rat kidney cells through cooperation 
between adenoviral E1A protein and NICD does not require the RBPJκ/CSL binding 
domain of NICD, suggesting transformation in this system may be non-canonical. 
However, this non-canonical Notch signaling still required nuclear localization of NICD 
to be oncogenic [186, 187].  
Studies in the Screpanti lab showed that non-canonical Notch3 signaling regulates 
T-cell development and leukemia through activation of the NFκB pathway. In their 
transgenic mouse model, Notch3 was overexpressed specifically in T cells and this led to 
development of leukemia [188].  This group showed that increased Notch3 expression 
enabled constitutive activation of NFκB and demonstrated that Notch3 interacts with 
IKKα to maintain NFκB activity [188]. Additionally, in breast cancer cells non-canonical 
Notch signaling is known to regulate IL-6 expression. IL-6 acts on tumor cells to further 
increase their oncogenic potential [189]. Cytoplasmic NICD was sufficient to engage 
with the non-canonical NFκB pathway to induce IL-6 expression [189]. Taken together, 
these studies support a role for non-canonical Notch signaling via NFκB pathway in 
oncogenesis.  
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In human myelogenous leukemia cells, Notch1 directly interacts with the 
transcription factor, YY1, to drive expression of oncogenic transcription factor c-myc 
independent of CSL [190]. In HPV-driven human cervical cancer, non-canonical Notch 
signaling enables oncogenesis, independent of CSL, via PI3K pathway [191]. However 
little is known about how non-canonical Notch signaling drives transformation in these 
situations.  
In this study we examined the effect of differential localization of Notch1 in the 
induction of T-ALL. Localization to the cytoplasm implicates non-canonical role of 
Notch1 in the disease induction. We used two different constructs previously generated in 
our lab. One of them has extra nuclear localization signals (NLS) and the other construct 
has extra nuclear export signals (NES). Bone marrow cells were infected with these two 
different constructs as well as a positive control plasmid to express Notch1 in the cells 
and eventually induce T-ALL. At day 40 mice were sacrificed to analyze thymii and 
spleens for CD4 and CD8 double positive cell percentages. Compared to control un-
induced Bone marrow cells injected mice, both Notch1 NLS and Notch1 NES constructs 
infected cells injected mice had an increase in CD4 and CD8 double positive cell 
population (Figure 29). When we analyzed the thymii of these groups, Notch1 NES 
infected cell containing mice had more robust increase in CD4 and CD8 double positive 
cells compare to Notch1 NLS infected cells injected mice group (Figure 29). This 
preliminary study suggests that cytoplasmic Notch1 was more potent to induce T-ALL, 
based on CD4 and CD8 double positive cell numbers in thymii, compared to nuclear 
Notch1. It supports that non-canonical cytoplasmic signaling of Notch1 is more crucial in 
the induction of T-ALL than canonical Notch1 signaling. It is worth to repeat these 
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experiments and also to do further analysis in terms of number of cancer stem cells when 
T-ALL was induced by differentially localized Notch1 proteins. Furthermore, studying 
the signaling pathways differentially activated in cancerous cells from these T-ALL 
induced mice.      
It is important to note that inhibitors are available for many of the signaling 
pathways involved in non-canonical Notch signaling (NF-κB, PI3K, AKT, mTOR, HIF-
1α and β-catenin) and, in several instances, these inhibitors have passed through clinical 
trials [122].  Thus, in the near future, it should be feasible to test the possibility that 
combination therapy using Notch inhibitors, in addition to inhibitors of these other 
pathways, might prove more efficacious in the treatment of diseases regulated by Notch. 
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Figure 29: Nuclear versus Cytoplasmic localization of Notch1 regulates CD4 
and CD8 double positive cell levels in Thymii and the spleen of mice 
A) CD4 and CD8 double staining and FACS analysis for the spleen of mice with 
bone marrow re-constituted by the cells infected with control plasmid, Notch1 
intracellular domain (N1IC) positive control plasmid, Notch1 Nuclear Localization 
Signal (NLS) plasmid, Notch1 Nuclear Export Signal (NES) plasmid. B) CD4 and 
CD8 double staining and FACS analysis for the thymii of mice with bone marrow 
re-constituted by the cells infected with control plasmid, Notch1 intracellular 
domain (N1IC) positive control plasmid, Notch1 Nuclear Localization Signal 
(NLS) plasmid, Notch1 Nuclear Export Signal (NES) plasmid. N=3 for each group.  
At day 40 after bone marrow reconstitution mice were sacrificed for analysis. 
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